Pharmaceutical kit for parenteral combination administration

The parenteral co-administration pharmaceutical kit with anti-inflammatory drugs addresses inflammatory responses and enhances bioavailability by using biodegradable polymers and local anesthetics to manage inflammation and improve drug delivery.

JP2024542112AActive Publication Date: 2024-11-13G2GBIO INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2024526664
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-01
Filing Date
2022-11-07
Publication Date
2024-11-13
Estimated Expiration
2042-11-07

AI Technical Summary

Technical Problem

Parenteral drug carriers can induce inflammatory responses and chronic inflammation, and excessive or inappropriate drug release can lead to side effects and reduced efficacy, necessitating the development of anti-inflammatory preparations to prevent, reduce, or treat inflammation and improve bioavailability.

Method used

A parenteral co-administration pharmaceutical kit comprising formulations with anti-inflammatory drugs to prevent or treat inflammatory responses, regulate drug carrier degradation, and enhance bioavailability, utilizing biodegradable polymers and local anesthetics to manage inflammation and improve drug delivery.

Benefits of technology

The kit effectively reduces inflammatory reactions, minimizes side effects, and enhances bioavailability of co-administered drugs by maintaining controlled drug release, thereby improving therapeutic efficacy and patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542112000001_ABST
    Figure 2024542112000001_ABST
Patent Text Reader

Abstract

The present invention provides a pharmaceutical kit for parenteral combination administration comprising a first formulation containing a first drug and a second formulation containing a second drug and a parenteral drug delivery vehicle, the kit being capable of being used to prevent, reduce or treat an inflammatory response in a subject by the drug delivery vehicle contained in the second formulation, to regulate the degradation of a parenteral drug delivery vehicle contained in the second formulation, or to increase the bioavailability of a second drug contained in the second formulation.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a parenteral combination pharmaceutical kit, which utilizes an anti-inflammatory drug to improve the bioavailability of a co-administered drug, prevent, reduce or treat an inflammatory response caused by a co-administered parenteral drug delivery system, or modulate the degradation of a co-administered parenteral drug delivery system. [Background technology]

[0002] A large number of combination drugs have been developed in which two or more drugs are administered in various ways for various reasons, such as increasing efficacy of drugs, reducing side effects, or convenience of administration.

[0003] In addition, drug delivery systems (DDS) are used to maximize the therapeutic effects of drugs and minimize side effects in the human body. Drug delivery systems range from simple combinations with drugs to dosage forms with advanced functions, and are administered to patients through various routes in the human body, such as oral, injection, transdermal, mucosal, and implantation. In particular, for drugs that must be taken for a long period of time to treat diseases, active development is being conducted on various types of drug formulations for parenteral administration that contain drugs to improve the convenience of taking the drugs and the therapeutic effects of the drugs.

[0004] However, such dosage forms use a technology in which a substance that does not exist in the body is used as a drug delivery vehicle to load the target drug and release the therapeutic agent in the body over a long period of time. Therefore, the drug delivery vehicle, as a foreign body, may induce undesirable reactions, such as immune or inflammatory reactions, in the recipient.

[0005] Such inflammatory reactions are likely to progress from acute inflammation to chronic inflammation, as they continue to persist until the parenteral drug delivery system carrying the target drug is completely decomposed in the body. Therefore, there is a need for an anti-inflammatory preparation or kit for preventing, reducing or treating inflammation in a subject administered with a drug delivery system.

[0006] On the other hand, if excessive or inappropriate release of a drug occurs in a long-lasting drug formulation, the target drug release profile cannot be achieved, which may result in side effects or failure to ensure the expected drug efficacy.

[0007] In addition, when it is desired to release a drug continuously for a long period of time, a large amount of drug must be introduced into the drug delivery system to provide sufficient pharmacological efficacy for the desired period of time. If the bioavailability of the drug contained in the formulation is low, an excessively large amount of drug delivery agent must be administered to provide a long-term effective pharmacological effect. However, when a large amount of drug delivery agent is administered into the body, it cannot be administered by subcutaneous injection, and it is difficult for the patient to administer it directly (self-administration), or it may be necessary to inject it into multiple sites, which may cause problems such as pain and inflammatory reactions at the administration site. Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention relates to a parenteral combination pharmaceutical kit, which utilizes an anti-inflammatory drug to improve the bioavailability of a co-administered drug, prevent, reduce or treat an inflammatory response caused by a co-administered parenteral drug delivery system, or modulate the degradation of a co-administered parenteral drug delivery system.

[0009] One example of the present invention provides a parenteral combination pharmaceutical kit or use thereof utilizing an anti-inflammatory drug to prevent, reduce or treat an inflammatory response due to a co-administered parenteral drug delivery vehicle.

[0010] Another embodiment of the present invention provides a parenteral co-administration pharmaceutical kit or use thereof for controlling the degradation rate of a co-administered parenteral drug carrier using an anti-inflammatory drug.

[0011] Yet another embodiment of the present invention provides a parenteral combination pharmaceutical kit or use thereof that utilizes an anti-inflammatory drug to increase the bioavailability of the co-administered drug.

[0012] Yet another embodiment of the present invention relates to a parenteral formulation or kit which additionally contains a local anesthetic component in addition to the parenteral combination administration pharmaceutical kit. [Means for solving the problem]

[0013] One example of the invention is a parenteral combination administration pharmaceutical kit comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug delivery vehicle, The present invention relates to a parenteral combination administration pharmaceutical kit or use thereof, wherein the first formulation comprises an anti-inflammatory first drug, or an anti-inflammatory first drug carried in a first parenteral drug delivery vehicle, the second formulation comprises a second parenteral drug delivery vehicle and a second drug different from the drug of the first formulation, and the first formulation is for preventing, reducing or treating an inflammatory response in a subject by the parenteral drug delivery vehicle of the second formulation.

[0014] One example of the invention is a parenteral combination administration pharmaceutical kit comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug delivery vehicle, The present invention relates to a parenteral combination administration pharmaceutical kit, wherein the first formulation comprises a first anti-inflammatory drug or a first anti-inflammatory drug carried in a first parenteral drug vehicle, the second formulation comprises a second parenteral drug vehicle and a second drug different from the drug of the first formulation, and the first formulation is for regulating the degradation of the parenteral drug vehicle contained in the second formulation.

[0015] One example of the present invention relates to a pharmaceutical kit for parenteral combination administration comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug vehicle, wherein the first formulation comprises an anti-inflammatory first drug, or an anti-inflammatory first drug carried in a first parenteral drug vehicle, and the second formulation comprises a second parenteral drug vehicle and a second drug different from the drug of the first formulation, and the first formulation is intended to increase the bioavailability of the second drug contained in the second formulation.

[0016] The first and second preparations included in the pharmaceutical kit for parenteral combination administration may be administered simultaneously or at different times. The pharmaceutical kit for parenteral combination administration may include the first and second preparations in the form of a mixed preparation or separate preparations.

[0017] A parenteral combination administration pharmaceutical kit according to the present invention can include a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug vehicle.

[0018] The first drug in the first formulation may be an anti-inflammatory drug, and the first drug may be different from the second drug in the second formulation, and the first drug may be provided without a separate drug vehicle, co-carried in the drug vehicle of the second formulation, or provided separately in the first parenteral drug vehicle.

[0019] For example, when the first drug included in the pharmaceutical kit is provided without a separate drug delivery vehicle, it may be provided in the form of a mixed formulation of a second formulation containing a second drug and a second parenteral drug delivery vehicle together with the first drug, or the first drug may be provided separately from the second formulation at a different time. Specifically, when the second formulation is a microparticle, the first drug may be provided together with the second drug in a form supported on a single microparticle.

[0020] Alternatively, the first drug contained in the pharmaceutical kit may be provided in a form supported by a separate first drug delivery vehicle, and the first drug delivery vehicle may be the same as or different from the second drug delivery vehicle. Specifically, when the first formulation contains the first drug supported by a first parenteral drug delivery vehicle, it may be provided in the form of a mixed formulation or a separate formulation with the second formulation, and may be administered to a subject in need thereof at the same time or at different times.

[0021] In another embodiment of the present invention, the AUC at or above the minimum effective blood concentration of the anti-inflammatory drug released from the first anti-inflammatory preparation may be 1 / 2 or less, 1 / 3 or less, 1 / 5 or less, or 1 / 10 or less of the total AUC of the daily effective dose of the drug, or may be 50% or less, 33% or less, 20% or less, or 10% or less based on the total AUC100% of the daily effective dose of the drug. For example, the AUC when the first anti-inflammatory preparation containing dexamethasone is administered to the human body and the blood drug concentration is 1 ng / ml or more may be 1 / 2 or less, preferably 1 / 3 or less, more preferably 1 / 5 or less, and most preferably 1 / 10 or less, compared to the total AUC when 6 mg / dose of oral preparation is administered.

[0022] In a specific example, the anti-inflammatory drug released from the anti-inflammatory first formulation may be one that is released so that the plasma concentration of the anti-inflammatory drug is 1.0 ng / mL or less, and in this case, a preferred example of the anti-inflammatory drug may be dexamethasone or a derivative thereof, or a pharmaceutical salt thereof.

[0023] According to one embodiment of the present invention, the first drug (anti-inflammatory drug) contained in the first formulation may sometimes induce side effects if its blood concentration is too high in the sustained release formulation. For example, if the anti-inflammatory drug is a glucocorticoid, sometimes high plasma concentrations (administered at 1 mg / kg / day for 2-3 weeks) may lead to systemic side effects, and it is preferable to have a low plasma concentration compared to the concentration at the local administration site.

[0024] In yet another example of the present invention, in the blood concentration curve over time after administration of the anti-inflammatory drug released from the anti-inflammatory first formulation, the AUC above the minimum blood concentration that induces side effects in the whole body must be minimized, and specifically, it may be 1 / 10 or less, 1 / 20 or less, 1 / 30 or less, or 1 / 40 or less of the AUC when the same dose of the drug is administered in a single dose, or it may be 10% or less, 5% or less, 3.3% or less, or 2.5% or less based on AUC100% when the same dose of the drug is administered in a single dose.

[0025] For example, when an anti-inflammatory first formulation containing dexamethasone or dexamethasone acetate is subcutaneously administered to a rat, the AUC when the blood drug concentration is 2 ng / ml or more may be 1 / 10 or less, preferably 1 / 20 or less, more preferably 1 / 30 or less, and most preferably 1 / 40 or less, of the AUC when the same dose of dexamethasone or dexamethasone acetate is subcutaneously administered.

[0026] In a specific example, the anti-inflammatory drug released from the anti-inflammatory first formulation may be one that is released so that the plasma concentration of the anti-inflammatory drug is 2.0 ng / mL or less. In this case, a preferred example of the anti-inflammatory drug may be dexamethasone or a derivative thereof or a pharmaceutical salt thereof.

[0027] In the present specification, the terms "drug delivery medium", "drug delivery system", "drug carrier" or "drug carrier" may be used interchangeably and refer to a delivery medium from which a pharma- ceutical active ingredient can be released when administered to a living body. The drug delivery medium applicable to the present invention is intended to include all parenteral drug delivery mediums such as microspheres, liposomes, micelles, depots, or hydrogels. The hydrogels include injectable gels. The drug delivery medium can be a biocompatible material that can be used as a carrier for delivering a drug to a living body, and is preferably a biodegradable material for drug release. For example, the material of the drug delivery medium includes, but is not limited to, biodegradable polymers and biodegradable lipids.

[0028] The drug carrier applicable to the present invention may be a biocompatible material, including, but not limited to, biodegradable polymers and biodegradable lipids.

[0029] Specifically, the type of biodegradable polymer is not particularly limited, but preferably, polyester can be used. Examples of biodegradable polymers include polylactide (PLA), polyglycolide (PGA), a copolymer of lactide and glycolide, poly(lactide-co-glycolide) (PLGA), polydioxanone, polycaprolactone (PCL), polylactide-co-glycolide-co-caprolactone (PLGC), polylactide-co-hydroxymethylglycolide (PLGC), poly(hydroxymethyl) ... glycolide, PLGMGA), Polyalkylcarbonate, Polytrimethylenecarbonate (PTMC), Polylactide-co-trimethylenecarbonate (PLTMC), Polyhydroxybutyric acid (PHB), Polyhydroxybutyrate-co-hydroxyvalerate (PHBV), Polyorthoester, Polyanhydride, Polyanhydride-co-imide, Polypropylene fumarate, Pseudopolyamino acidIt is preferable to use one or more polymers, preferably two or more polymers, selected from the group consisting of a polymer selected from the group consisting of polyaminoacid, polyalkylcyanoacrylate, polyphosphazene, polyphosphoester, polysaccharide, and poly(butylene succinate lactide) (PBSLA), a simple mixture of two or more polymers, a copolymer of the polymer and polyethylene glycol (PEG), and a polymer-sugar complex in which the polymer or copolymer is bound to a sugar. As a specific embodiment, poly(lactide-co-glycolide) and / or polylactide polymer can be used as the biodegradable polymer in the preparation method according to the present invention.

[0030] In the present specification, when the first formulation contains an anti-inflammatory drug and a first drug delivery vehicle, the drug delivery vehicle of the first formulation and the drug delivery vehicle of the second formulation may be the same or different in terms of material, size, dosage form, etc., and may be, for example, the same dosage form. For example, the first drug delivery vehicle and the second drug delivery vehicle may be microspheres having various materials and / or sizes, respectively.

[0031] The drug delivery vehicle of the first formulation is referred to herein as a first parenteral drug delivery vehicle, which is not particularly limited as long as it satisfies the desired anti-inflammatory drug release characteristics, and it is preferable that the first drug delivery vehicle contained in the anti-inflammatory formulation has lower pro-inflammatory properties and / or a lower content thereof.

[0032] The drug delivery agent contained in the second formulation is a drug delivery agent used to deliver a drug used for the prevention, amelioration or treatment of a disease, which may be a cause of inflammation, and may include, but is not limited to, for example, biodegradable polymers, biodegradable lipids, etc.

[0033] The microspheres include microparticles or nanoparticles, and are usually prepared by including a biodegradable polymer. In one example, when the first drug delivery vehicle is a microsphere, the microsphere may have an average particle size of, for example, 10 to 100 micrometers. The second drug delivery vehicle may be a microsphere, specifically, a microsphere having an average particle size of 10 to 100 micrometers.

[0034] A specific example of the invention includes an anti-inflammatory first formulation comprising an anti-inflammatory drug and a first parenteral drug delivery vehicle, and a second formulation comprising a second parenteral drug delivery vehicle, The first and second parenteral drug delivery vehicles contain biodegradable substances, and the second parenteral drug delivery vehicle is an inflammatory delivery vehicle that induces inflammation in a subject. The anti-inflammatory first formulation relates to a parenteral anti-inflammatory kit for preventing, reducing or treating an inflammatory response in a subject caused by the drug delivery vehicle of the second formulation. The second formulation may further contain a pharma- ceutical active ingredient different from the anti-inflammatory drug of the first formulation.

[0035] The first and second anti-inflammatory preparations may be included in a mixed preparation or separate preparations, and may be administered at different times or simultaneously.

[0036] The first formulation and the second formulation may have a solid content of 0.002 to 20 parts by weight, specifically 0.002 to 15 parts by weight, 0.002 to 10 parts by weight, etc., based on 100 parts by weight of the solid content of the second formulation, and the second formulation may or may not contain a drug.

[0037] When the first and second formulations are provided as a mixed formulation, the anti-inflammatory drug may be contained in an amount of 0.001 to 5.0 wt% based on 100 wt% solid content of the mixed formulation, specifically, 0.001 to 5.0 wt%; 0.001 to 4.0 wt%; 0.001 to 3.0 wt%; 0.001 to 2.0 wt%; or 0.001 to 1.0 wt%.

[0038] When the first formulation and the second formulation are provided as a mixed formulation, the first drug delivery agent may be contained in an amount of 0.002 to 20 wt % based on 100 wt % solid content of the mixed formulation.

[0039] When the pharmaceutical kit for parenteral combined administration according to one embodiment of the present invention is for preventing, reducing or treating an inflammatory response of a subject by the parenteral drug delivery of the second formulation, it may include an anti-inflammatory first formulation containing an anti-inflammatory drug as a first drug, or an anti-inflammatory drug and a first parenteral drug delivery, and a second formulation in which a second drug different from the anti-inflammatory drug of the first formulation is carried by a second parenteral drug delivery. In this case, the anti-inflammatory first drug contained in the anti-inflammatory first formulation may be released during the same period as the administration interval of the second formulation or during a part of the administration interval of the second formulation to achieve anti-inflammatory efficacy.

[0040] In another example, the anti-inflammatory drug contained in the anti-inflammatory first formulation may be released at a relatively uniform concentration during the release period, or may be released at a relatively high concentration during a certain period, for example, during an early period or a late period of 50% or less, 40% or less, 30% or less, 20% or less, or 10% or less of the entire administration interval of the second formulation, depending on the characteristics required for the second formulation. In another example, the anti-inflammatory drug contained in the anti-inflammatory first formulation may be released at a concentration proportional to the remaining amount of the parenteral second drug delivery agent contained in the second formulation, and specifically, the drug release amount of the first formulation may be released at a gradually decreasing content according to the relative content (weight %) of the second drug delivery agent remaining at the administration site, based on 100% by weight of the second drug delivery agent contained in the second formulation at the start of administration or before administration.

[0041] Furthermore, when the anti-inflammatory drug contained in the first formulation induces an increase in blood glucose level in a subject due to its blood concentration, the concentration at which the blood glucose level increase can be at an acceptable level becomes the upper limit of the anti-inflammatory drug release amount, and the amount effective for preventing, ameliorating or treating an inflammatory response caused by the second drug carrier contained in the second formulation can be set as the lower limit of the anti-inflammatory drug release amount, and the range of the anti-inflammatory drug release amount can be appropriately set within a range that combines the upper and lower limits.

[0042] In the present invention, the term "individual" or "subject" includes mammals, particularly humans, and the administration schedule, administration interval, dosage, etc. can be easily set, changed, or adjusted by those skilled in the art depending on the factors mentioned above.

[0043] The present invention uses a first anti-inflammatory formulation containing an anti-inflammatory drug together with a second formulation containing a drug effective in the prevention, alleviation or treatment of a disease, thereby alleviating the inflammatory reaction caused by the drug carrier of the second formulation at the administration site from the early stage of inflammation development after administration, inhibiting the progression to chronic inflammation, and reducing side effects such as edema, erythema and tissue hardening at the administration site, thereby improving patient rejection and satisfaction, and improving the therapeutic effect by administering a parenteral formulation loaded with a therapeutic agent once or repeatedly during the period required for treatment.

[0044] The present invention provides a dosage form that can suppress inflammation only at the site where the parenteral anti-inflammatory formulation is administered without side effects due to systemic exposure of the anti-inflammatory drug, by having a first formulation containing an anti-inflammatory drug at a low concentration that exerts anti-inflammatory efficacy locally at the site where inflammation is induced when administered together with a drug, and by continuously releasing the anti-inflammatory drug until the drug carrier contained in the second formulation is completely decomposed.

[0045] In the present specification, the first anti-inflammatory formulation may contain only an anti-inflammatory drug, or may contain an anti-inflammatory drug and a first drug delivery system. When the first anti-inflammatory formulation contains an anti-inflammatory drug and a first drug delivery system, the anti-inflammatory drug may constitute about 1% by weight to about 90% by weight, about 2% by weight to about 90% by weight, about 5% by weight to about 90% by weight, 10% by weight to about 90% by weight, or about 10% by weight to about 80% by weight based on 100% by weight of the first drug delivery system contained in the first formulation.

[0046] In the present specification, when the first drug is carried together with the second drug in a single drug delivery vehicle, such as a microparticle, the first drug contained therein may be about 0.001% by weight, 0.005% by weight, 0.01% by weight, 0.05% by weight, 0.1% by weight, 0.2% by weight, 0.5% by weight, 1% by weight, or 5% by weight of the total drug delivery vehicle.

[0047] As used herein, "active ingredient," "active drug," "active ingredient," "active formulation," "drug" and "therapeutic formulation" are used interchangeably herein and refer to any substance used to prevent, ameliorate or treat a disease of interest.

[0048] In the present invention, the anti-inflammatory drug contained in the first anti-inflammatory preparation includes, but is not limited to, a steroid preparation, compound, or drug that, when administered in a pharma- ceutical effective amount, prevents, reduces, or treats inflammation, regulates the degradation of a drug carrier in a second preparation used in combination, or increases the bioavailability of a second drug used in combination.

[0049] More specifically, the anti-inflammatory drug means a drug for preventing, reducing or treating an inflammatory response in a subject, which occurs when a parenteral drug delivery system for delivering a drug for preventing, reducing or treating a disease in a subject is administered to the subject, and may be, for example, a drug for preventing, reducing or treating an inflammatory response that occurs locally at the administration site by a drug delivery system for parenteral delivery of an active ingredient for preventing, reducing or treating a disease in a subject.

[0050] In order to manage inflammation that has already developed, it is possible to use nonsteroidal anti-inflammatory drugs and steroidal analgesics that are commonly used in the treatment of inflammation. However, since they are administered together with a therapeutic sustained-release preparation, it is more preferable to use a steroidal anti-inflammatory drug, which has a strong anti-inflammatory effect, since it exerts an anti-inflammatory effect even in small amounts.

[0051] However, in the case of steroidal anti-inflammatory drugs, high drug plasma levels usually cause systemic side effects such as hypertension, hyperglycemia, osteoporosis, cataracts, glaucoma, and gastric ulcers, and when used for a long period of time, resistance occurs and the drug does not show its efficacy. Due to side effects of such systemic exposure, when administered by oral or intravenous injection, which is the conventional method of administering steroid dosage forms, systemic exposure is induced for a long period of time until the sustained-release injection containing the therapeutic agent is decomposed in the body, making long-term use impossible.

[0052] Anti-inflammatory agents include, for example, non-steroidal anti-inflammatory agents, including, but not limited to, aspirin, diclofenac, flurbiprofen, ibuprofen, ketorolac, naproxen, and suprofen. In one example, the anti-inflammatory agent includes a combination of two or more non-steroidal anti-inflammatory agents.

[0053] More specifically, the nonsteroidal anti-inflammatory drugs include aceclofenac, acemetacin, alminoprofen, amfenac, apazone, aspirin, bromfenac, bufexamac, celecoxib, choline salicylic acid, and the like. salicylate, cinnoxicam, clonixin, dexibuprofen, dexketoprofen, diclofenac, diflunisal, emorfazone, etodolac, etoricoxib, ethenzamide, felbinac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, imidazole salicylate salicylate, indomethacin, isopropylantipyrine, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamate, meloxicam, mefenamic acidacid, morniflumate, nabumetone, naproxen, nefopam, nimesulide, oxaprozin, oxyphenbutazone, pelubiprofen, phenylbutazone, piroxicam, pranoprofen, proglumetacin, rofecoxib, salsalate, salicylate, sulindac, talniflumate, tenoxicam, tiaprofenic acid, tolfenamic acid Acid, tolmetin, valdecoxib, zaltoprofen, and pharma- ceutical acceptable salts thereof.

[0054] Anti-inflammatory agents include drugs that, when administered in a prophylactically or therapeutically effective amount, prevent, reduce or treat inflammation, and can specifically include "steroidal anti-inflammatory agents," "corticoids" or "corticosteroids," and "glucocorticoids," and anti-inflammatory agents can include combinations of two or more steroidal anti-inflammatory agents.

[0055] Steroidal anti-inflammatory agents that can be used in the present invention include 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximethasone, dexamethasone, cyclosporine ... tazon, dexamethasone acetate, dexamethasone phosphate, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, flucortine butyl, flucortolone, fluorometholone, fluperolone acetate acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, and any derivatives thereof.

[0056] The corticosteroids include beclomethasone dipropionate, betamethasone, budesonide, deflazacort, dexamethasone, dexamethasone acetate, dexamethasone phosphate, difluprednate, epinephrine, fludrocortisone, fluocinolone acetonide, and the like. acetonide, fluocortin, fluorometholone, fluticasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, and pharma- ceutical acceptable salts thereof.

[0057] The second drug, which is the active ingredient contained in the second formulation herein, may be, for example, a drug that parenterally delivers an active ingredient for the prevention, alleviation or treatment of a disease or condition of a subject. The active ingredient that may be contained in the second formulation may be an active ingredient for the prevention, alleviation or treatment of a disease or condition of a subject that is different from the anti-inflammatory drug of the anti-inflammatory first formulation.

[0058] Specifically, the type of active ingredient that may be contained in the second formulation is not particularly limited, and examples thereof include dementia treatments; Parkinson's disease treatments; anticancer drugs; antipsychotic drugs such as antianxiety drugs, antidepressants, neuroleptics, and psychotropic drugs; circulatory system drugs such as hyperlipidemic drugs, hypertension treatments, hypotension treatments, antithrombotic drugs, vasodilators, and antiarrhythmic drugs; epilepsy treatments; gastrointestinal treatments such as antiulcer drugs; rheumatism drugs; antispasmodics; tuberculosis treatments; muscle relaxants; osteoporosis treatments; erectile dysfunction treatments; hemostatic agents; hormones such as sex hormones; diabetes treatments; antibiotics; antifungal drugs; antiviral drugs; antipyretic analgesics and anti-inflammatory drugs; autonomic nerve regulators; diuretics; antidiuretics; analgesics; antihistamines; antiprotozoal drugs; antianemia drugs; antiasthma drugs; anticonvulsants; antidotes; antimigraine drugs; antiemetics; anti-Parkinson's disease The therapeutic agent may be selected from the group consisting of drugs; antiepileptic drugs; antiplatelet drugs; antitussives and expectorants; bronchodilators; cardiac stimulants; immunomodulators; protein drugs; genetic drugs; and mixtures thereof, and may be preferably selected from the group consisting of dementia treatment drugs, Parkinson's disease treatment drugs, anticancer drugs, antipsychotic drugs, hyperlipidemic treatment drugs, hypertension treatment drugs, epilepsy treatment drugs, gastrointestinal treatment drugs, rheumatism drugs, antispasmodics, tuberculosis treatment drugs, muscle relaxants, antiarrhythmic drugs, osteoporosis treatment drugs, erectile dysfunction treatment drugs, hemostatic agents, antiviral drugs, hormone drugs, antibiotics, diabetes treatment drugs, antifungal drugs, antithrombotic drugs, antipyretic analgesic and anti-inflammatory agents, and mixtures thereof.

[0059] The active ingredient that can be contained in the second formulation may be a small molecule compound, a protein, an antibody, a synthetic compound, a nucleic acid molecule, or a peptide. The nucleic acid molecule may be one or more selected from the group consisting of DNA, RNA, microRNA (miRNA), small RNA (smRNA), small interfering RNA (siRNA), Piwi-interacting RNA (piRNA), small nucleolar RNA (snoRNA), tRNA-derived small RNA (tsRNA), small rDNA-derived RNA (srRNA), small nuclear RNA (U-RNA), and long noncoding RNA (lncRNA).

[0060] Among the above-mentioned types of drugs, preferred are donepezil, memantine, rivastigmine, entecavir, lamivudine, rotigotine, ropinirole, buprenorphine, fentanyl, nimodipine, granisetron, cytarabine, carmustine, tamseroeucin, pharmacoxib, testosterone, estradiol, risperidone, paliperidone, olanzapine, aripiprazole, and gossip. The agent may be selected from the group consisting of Relin, Leuprolide, Triptorelin, Buserelin, Naparelin, Deslorelin, Octreotide, Pasireotide, Lanreotide, Valpretide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, 5-alpha reductase inhibitors (e.g., Finasteride, Dutasteride, etc.), Tirzepatide, Dulaglutide, Insulin glargine, Insulin degludec, Insulin icodec, Cagrilintide, and salts thereof, and mixtures of two or more thereof.

[0061] The pharmaceutical kit for parenteral combined administration according to one embodiment of the present invention may further include a local anesthetic component in addition to the first anti-inflammatory formulation and / or the second formulation. The local anesthetic component may be used as a drug directly together with the first formulation, the second formulation, or a mixed formulation of the first formulation and the second formulation, or may be supported by a separate appropriate drug carrier.

[0062] Another embodiment of the present invention relates to a pharmaceutical kit for parenteral combination administration that regulates degradation of a parenteral drug carrier of an anti-inflammatory drug and a second formulation used in combination therewith, specifically, the kit includes a first formulation including an anti-inflammatory first drug or an anti-inflammatory first drug and a first parenteral drug carrier, and a second formulation including a parenteral second drug carrier, the first parenteral drug carrier and the second parenteral drug carrier including a biodegradable polymer, The first formulation or the drug contained in the first formulation modulates the degradation rate of the second parenteral drug delivery vehicle, in the parenteral combination pharmaceutical kit, parenteral formulation or kit.

[0063] The second preparation may further contain a pharma- ceutical active ingredient different from the anti-inflammatory drug of the first preparation, and the second preparation is as described above.

[0064] The first formulation or the anti-inflammatory drug contained in the first formulation can adjust the release rate of the drug contained in the second formulation by adjusting the decomposition rate of the second parenteral drug delivery vehicle. Adjusting the decomposition rate of the second parenteral drug delivery vehicle may preferably be to slow down the decomposition rate of the second parenteral drug delivery vehicle to extend the release period of the drug.

[0065] The anti-inflammatory drug contained in the first formulation is as described above and may be, for example, but is not limited to, dexamethasone free base, dexamethasone acetate, or dexamethasone phosphate.

[0066] In addition, in the parenteral combination pharmaceutical kit for adjusting the decomposition rate of the second parenteral drug delivery vehicle, the first formulation and the second formulation may be contained in a mixed formulation or separate formulations, or may be administered at different times or simultaneously.

[0067] The first formulation and the second formulation may be such that the solid content of the first formulation is 0.002 to 20 parts by weight based on 100 parts by weight of the solid content of the second formulation, and the second formulation may or may not contain a drug.

[0068] When the first and second preparations are provided as a mixed preparation, the anti-inflammatory drug may be contained in an amount of 0.001 to 5.0 w / w% based on 100 wt% solid content of the mixed preparation.

[0069] In the present specification, when a first formulation includes an anti-inflammatory drug and a first drug delivery vehicle, and a second formulation includes an anti-inflammatory drug and a second drug delivery vehicle, and the first formulation and the second formulation are provided as a mixed formulation, the first drug delivery vehicle may be contained in an amount of 0.002 to 20 wt% based on the solid content of the mixed formulation being 100 wt%.

[0070] A parenteral pharmaceutical kit according to one embodiment of the present invention may include a first formulation including a first drug and a first parenteral drug carrier, and a second formulation including a pharma- ceutically active ingredient and a second parenteral drug carrier different from the first drug of the first formulation. In this case, the first drug contained in the first formulation may be released during the same period as the administration interval of the second formulation or during a part of the administration interval of the second formulation to achieve the intended efficacy. In another example, the first drug contained in the first formulation may be released uniformly at a certain concentration during the release period, or may be released at a relatively high or low concentration during a certain period, for example, during an early period or a late period of 50% or less, 40% or less, 30% or less, 20% or less, or 10% or less of the entire administration interval of the second formulation, depending on the characteristics required for the second formulation, and thus may have a non-uniform release characteristic. In another example, the first drug contained in the first formulation may be released at a concentration proportional to the remaining amount of the second drug delivery vehicle for parenteral use contained in the second formulation; specifically, the amount of drug released from the first formulation may be gradually reduced in accordance with the relative content (weight %) of the second drug delivery vehicle remaining at the administration site, based on a content of 100% by weight of the second drug delivery vehicle contained in the second formulation at the start of administration or before administration.

[0071] Furthermore, when the anti-inflammatory drug contained in the first formulation induces an increase in blood glucose level in a subject due to its blood concentration, the concentration at which the increase in blood glucose level can be at an acceptable level becomes the upper limit of the anti-inflammatory drug release amount, and the amount effective for preventing, ameliorating or treating an inflammatory response caused by the second drug carrier contained in the second formulation can be set as the lower limit of the anti-inflammatory drug release amount, and the range of the anti-inflammatory drug release amount can be appropriately set within a range that combines the upper and lower limits.

[0072] The material, dosage form, and characteristics of the drug delivery medium are as described above, and the active ingredient that can be contained in the second formulation are as described above.

[0073] One example of the present invention relates to a parenteral combination pharmaceutical kit or formulation comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug vehicle, wherein the first formulation comprises an anti-inflammatory first drug or an anti-inflammatory first drug carried by a first parenteral drug vehicle, and the second formulation comprises a second parenteral drug vehicle and a second drug different from the drug of the first formulation, wherein the first formulation is intended to increase the bioavailability of the second drug contained in the second formulation.

[0074] In the present invention, the first formulation comprising the first anti-inflammatory drug or the first anti-inflammatory drug carried in a first parenteral drug vehicle is a modulator or enhancer of the bioavailability of the second drug.

[0075] As used herein, the term "bioavailability" refers to the portion of a drug dose that reaches the systemic circulation unchanged and is one of the main pharmacokinetic properties of a drug. When a drug is administered intravenously, its bioavailability is 100%. When a drug is administered by a different route (e.g., orally), its bioavailability generally decreases and may vary from patient to patient. Bioavailability is an important variable in pharmacokinetics that is considered when calculating doses for non-intravenous routes of administration.

[0076] The parenteral combination administration pharmaceutical kit of the present invention may require a smaller drug dose and improve the pharmacokinetic profile and efficacy of the second drug compared to a single dosage form of the second formulation without the first formulation containing the first drug.

[0077] Due to the improvement of bioavailability according to the present invention, drugs used for applications such as intramuscular injections can be changed to a subcutaneous injection dosage form or can be formulated with a lower drug content. In other words, toxicity-related side effects can be reduced with fewer administrations or lower doses. In general, the pharmacokinetics and / or pharmacodynamics of subcutaneous therapy are improved, and have advantages over current intramuscular injections. For example, subcutaneous injections can be administered by the patient or a family member and can be performed at home or anywhere. Due to the improvement of bioavailability according to the present invention, there are advantages such as changing the administration route of the second formulation, reducing the dosage, and / or reducing the administration frequency. In addition, due to the improvement of bioavailability, the effective amount of the drug or the content of the drug loaded in the unit formulation can be reduced, and intramuscular injections can be changed to an administration route such as subcutaneous injection, and the administration frequency can be reduced to improve the patient's drug compliance.

[0078] The term "effective amount" refers to an amount of a therapeutic compound effective at the time of administration to achieve a desired therapeutic or prophylactic result for the period of time necessary. A "therapeutically effective amount" of a therapeutic compound can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to induce a desired response in the individual.

[0079] In a specific example, the use of the present invention to increase, enhance, or improve the bioavailability of a second drug includes an increase in Cmax and / or AUC, for example, a pharmaceutical kit for combined administration comprising a first formulation and a second formulation means an increase in Cmax and / or AUC of the second drug compared to a single dosage form of the second formulation not including the first formulation. More specifically, a pharmaceutical kit for combined administration comprising the same second formulation and the first formulation as the single dosage form may have a Cmax of 1.1 times or more, 1.2 times or more, 1.3 times or more, 1.4 times or more, 1.5 times or more, 2.0 times or more and / or an AUC of 120% or more, 130% or more, 150% or more, 200% or more, 250% or more, 300% or more compared to a single dosage form of the second formulation.

[0080] The material, dosage form, or characteristics of the drug delivery vehicle are as described above, and the active ingredient that can be contained in the second formulation is also as described above. In addition, the use of improving bioavailability according to the present invention is to improve the bioavailability of the second drug contained in the second formulation described above, and specific examples of the second drug include, but are not limited to, donepezil, rivastigmine, semaglutide, leuprolide, octreotide, finasteride, etc.

[0081] A specific example of the present invention relates to a parenteral combination pharmaceutical kit that utilizes an anti-inflammatory drug in a first formulation to improve the bioavailability of a co-administered drug (a drug in a second formulation).

[0082] There are known parenteral preparations, such as microsphere preparations, that carry drugs together with biodegradable polymers to release the drugs for a long period of time. However, drugs encapsulated in microspheres have low bioavailability, and therefore a large amount of microspheres must be administered to demonstrate a long-lasting pharmacological effect. However, when administering a large amount of microspheres into the body, there are problems in that it is difficult to administer them directly (self-administration) by the patient because of the difficulty of subcutaneous injection, and that pain and inflammatory reactions at the administration site are very high. Thus, the present invention relates to a pharmaceutical kit for parenteral combination administration that includes a second preparation containing a drug or its pharmacologic acceptable salt and a biodegradable polymer that improves the bioavailability of the drug and shows long-term stable drug release properties, and the first preparation.

[0083] More specifically, one embodiment of the present invention relates to a pharmaceutical kit for parenteral combination administration comprising a first formulation containing a first drug and a second formulation containing a second drug or a pharma- ceutically acceptable salt thereof and a parenteral drug delivery vehicle as a second drug, wherein the first formulation contains an anti-inflammatory first drug or an anti-inflammatory first drug carried in a first parenteral drug delivery vehicle, the second formulation contains a second parenteral drug delivery vehicle and a drug or a pharma- ceutically acceptable salt thereof as a drug of the second formulation, and the first formulation is for increasing or improving the bioavailability of the drug contained in the second formulation. In the present invention, the first formulation containing the anti-inflammatory first drug or the anti-inflammatory first drug carried in a first parenteral drug delivery vehicle is a regulator or enhancer of the bioavailability of the second drug.

[0084] When the first drug included in the pharmaceutical kit is provided without a separate drug delivery vehicle, the first drug may be provided in the form of a mixed formulation of a second formulation containing a second drug and a second parenteral drug delivery vehicle, or the first drug may be provided separately from the second formulation at a different time. Specifically, when the second formulation is a microparticle, the first drug may be provided together with the second drug in a form supported on a single microparticle.

[0085] Alternatively, the first drug contained in the pharmaceutical kit may be provided in a form supported by a separate first drug delivery vehicle, and the first drug delivery vehicle may be the same as or different from the second drug delivery vehicle. Specifically, when the first formulation contains the first drug supported by a first parenteral drug delivery vehicle, it may be provided in the form of a mixed formulation or a separate formulation with the second formulation, and may be administered to a subject in need thereof at the same time or at different times.

[0086] In the above example, the first formulation, the first drug contained in the first formulation, the first parenteral drug carrier that may be contained in the first formulation, and / or the second parenteral drug carrier contained in the second formulation are as described above, and the bioavailability, regulators or enhancers of the bioavailability of the second drug, etc. are as described above.

[0087] The pharmaceutical kit for parenteral combination administration according to the present invention can also be administered parenterally, for example, via subcutaneous injection. The second formulation can be composed of a drug portion and a solvent portion used to suspend the drug, and can be in the form of a double-chamber syringe in which the drug portion is contained in one chamber and the solvent portion in the other chamber, or a pre-filled syringe in which the drug portion is suspended in the solvent portion. When the second formulation is composed of a pre-filled syringe in which the drug portion is suspended in the solvent portion, the solvent portion used can be an injectable oil, including medium-chain oil, mineral oil, etc.

[0088] An example of a drug to be co-administered in the kit may be an active ingredient contained in the second formulation described above, and specifically may be selected from the group consisting of semaglutide, donepezil, rivastigmine, finasteride, octreotide, leuprolide, deslorelin, entecavir, salts thereof, derivatives thereof, and mixtures of two or more thereof.

[0089] For example, the pharma- ceutically acceptable salt of semaglutide may be sodium, nitrate, benzoate, hydroxynaphthoate, napadisylate or pamoate of semaglutide, the pharma-ceutically acceptable salt of semaglutide may be leuprolide acetate, the pharma-ceutically acceptable salt of tonepezil may be donepezil hydrochloride, the pharma-ceutically acceptable salt of rivastigmine may be rivastigmine tartrate, rivastigmine pamoate, other octreotide acetate, deslorelin acetate, etc.

[0090] The anti-inflammatory drug of the first formulation included in the kit may be the active ingredient included in the first formulation described above, and may be specifically selected from the group consisting of dexamethasone, meloxicam, ketorolac, salts thereof, derivatives, and mixtures of two or more thereof, and in particular dexamethasone and its derivatives include, but are not limited to, dexamethasone, dexamethasone acetate, dexamethasone phosphate, etc.

[0091] A pharmaceutical kit for parenteral combination administration comprising a second drug and / or a pharma- ceutically acceptable salt thereof according to a specific embodiment of the present invention can contain a high content of the second drug relative to its particle size, and has the advantage that it can have a high bioavailability when administered to the body, exhibits a long-lasting effect, and can reduce the unit dose, thereby minimizing pain and inflammatory reactions that may occur to patients upon administration.

[0092] The pharmaceutical kit for parenteral combination administration containing the second drug and / or a pharma- ceutical acceptable salt thereof has a high drug content compared to the content in microspheres, while suppressing initial excessive release of the drug that may cause fatal side effects, and has high bioavailability, thereby exhibiting sufficient efficacy for a desired period of time, thereby improving, preventing, or treating a disease.

[0093] In addition, the improvement in the bioavailability of the second drug according to the present invention is very advantageous in terms of maintaining the drug concentration according to the drug administration interval, since it can maintain an effective drug concentration even near the end of the unit administration period. For example, when the second drug is leuprolide, the improvement in the bioavailability of the present invention can solve the inflammation problem caused by the administration of the second preparation, and the improvement in the bioavailability of the second drug can improve side effects caused by a sudden increase (surge) in testosterone levels that occurs when the drug concentration decreases during a certain period around the end of the unit administration period, i.e., the start of the next administration.

[0094] In a specific example, the use of the present invention to increase, enhance, or improve the bioavailability of a second drug includes an increase in Cmax and / or AUC, for example, a pharmaceutical kit for combined administration comprising a first formulation and a second formulation means an increase in Cmax and / or AUC of the second drug compared to a single dosage form of the second formulation not including the first formulation. More specifically, a pharmaceutical kit for combined administration comprising the same second formulation and the first formulation as the single dosage form may have a Cmax of 1.1 times or more, 1.2 times or more, 1.3 times or more, 1.4 times or more, 1.5 times or more, 2.0 times or more and / or an AUC of 120% or more, 130% or more, 150% or more, 200% or more, 250% or more, 300% or more compared to a single dosage form of the second formulation.

[0095] More specifically, when the second drug is semaglutide, it is useful for preventing or treating diabetes, specifically type 2 diabetes, beta cell function preservation, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or degenerative neurological diseases such as Alzheimer's disease and Parkinson's disease. In the pharmaceutical kit for parenteral combination administration containing semaglutide and / or a pharma- ceutical acceptable salt thereof, the content of the second drug may be 5% by weight or more, 8% by weight or more, 9% by weight or more, 9.5% by weight or more, or 10% by weight or more, for example, 5 to 20% by weight, based on 100% by weight of the whole second formulation containing the second drug and a second parenteral drug carrier. In addition, in the pharmaceutical kit for parenteral combination administration, the unit dose of the second formulation (e.g., microspheres containing a biocompatible polymer) containing the semaglutide and / or a pharma- ceutical acceptable salt thereof and a parenteral drug carrier may be 10 to 800 mg.

[0096] In one example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is semaglutide or a salt thereof, the weight ratio of the first drug, dexamethasone (free base), to the second drug, semaglutide (free base), in the parenteral combination administration pharmaceutical kit containing both the first formulation and the second formulation may be in the range of 0.0001:1 to 1:1, preferably in the range of 0.004:1 to 0.2:1, and more preferably in the range of 0.001:1 to 0.05:1.

[0097] As an example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is donepezil or a salt thereof, in a pharmaceutical kit for parenteral combination administration containing both the first formulation and the second formulation, the weight ratio of the first drug, dexamethasone (free base), to the second drug, donepezil (free base), may be in the range of 0.00003:1 to 0.02:1, preferably in the range of 0.00006:1 to 0.001:1, and more preferably in the range of 0.0001:1 to 0.005:1.

[0098] When the second drug is donepezil, the content of the second drug in the pharmaceutical kit for parenteral combination administration may be 25 to 75% by weight or 27 to 75% by weight, based on 100% by weight of the entire second formulation containing the second drug and a second parenteral drug carrier. In addition, in the pharmaceutical kit for parenteral combination administration, the unit dose of the second formulation containing donepezil and / or a pharma- ceutical acceptable salt thereof and a parenteral drug carrier (e.g., microspheres containing a biocompatible polymer) may be 50 to 1,200 mg.

[0099] As an example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is rivastigmine or a salt thereof, in a pharmaceutical kit for parenteral combination administration containing both the first formulation and the second formulation, the weight ratio of the first drug, dexamethasone (free base), to the second drug, rivastigmine (free base), may be in the range of 0.0005:1 to 0.2:1, preferably in the range of 0.0001:1 to 0.1:1, and more preferably in the range of 0.00015:1 to 0.05:1.

[0100] When the second drug is rivastigmine, the content of the second drug in the pharmaceutical kit for parenteral combination administration may be 15-45% by weight or 20-40% by weight based on 100% by weight of the entire second formulation containing the second drug and a second parenteral drug carrier. In addition, the unit dose of the second formulation (e.g., microspheres containing a biocompatible polymer) containing rivastigmine and / or a pharma- ceutical acceptable salt thereof and a parenteral drug carrier in the pharmaceutical kit for parenteral combination administration may be 20-900 mg.

[0101] When the second drug is finasteride, the content of the second drug in the parenteral combination administration pharmaceutical kit may be 20-75 wt% or 30-70 wt% based on 100 wt% of the entire second formulation containing the second drug and a second parenteral drug delivery vehicle. In addition, the unit dose of the second formulation containing finasteride and / or a pharma- ceutical acceptable salt thereof and a parenteral drug delivery vehicle (e.g., microspheres containing a biocompatible polymer) in the parenteral combination administration pharmaceutical kit may be 15-450 mg or 20-300 mg.

[0102] In one example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is finasteride or a salt thereof, the weight ratio of the first drug, dexamethasone (free base), to the second drug, finasteride (free base), in the parenteral combination administration pharmaceutical kit containing both the first formulation and the second formulation may be in the range of 0.0003:1 to 0.3:1, preferably in the range of 0.0006:1 to 0.15:1, and more preferably in the range of 0.0009:1 to 0.1:1.

[0103] When the second drug is octreotide, the content of the second drug in the pharmaceutical kit for parenteral combination administration may be 15-45% by weight or 20-40% by weight based on 100% by weight of the entire second formulation containing the second drug and a second parenteral drug carrier. In addition, the unit dose of the second formulation (e.g., microspheres containing a biocompatible polymer) containing the octreotide and / or a pharma- ceutical acceptable salt thereof and a parenteral drug carrier in the pharmaceutical kit for parenteral combination administration may be 20-300 mg or 20-600 mg.

[0104] As an example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is octreotide or a salt thereof, the weight ratio of the first drug, dexamethasone (free base), to the second drug, octreotide (free base), in the parenteral combination administration pharmaceutical kit containing both the first formulation and the second formulation may be in the range of 0.0003:1 to 0.6:1, preferably in the range of 0.0006:1 to 0.3:1, and more preferably in the range of 0.0009:1 to 0.15:1.

[0105] When the second drug is leuprolide, the content of the second drug in the pharmaceutical kit for parenteral combination administration may be 5-25 wt% or 10-20 wt% based on 100 wt% of the entire second formulation containing the second drug and a second parenteral drug carrier. In addition, the unit dose of the second formulation containing leuprolide and / or a pharma- ceutical acceptable salt thereof and a parenteral drug carrier (e.g., microspheres containing a biocompatible polymer) in the pharmaceutical kit for parenteral combination administration may be 15-230 mg or 18-225 mg.

[0106] As an example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is leuprolide or a salt thereof, the weight ratio of the first drug, dexamethasone (free base), to the second drug, leuprolide (free base), in the parenteral combination administration pharmaceutical kit containing both the first formulation and the second formulation may be in the range of 0.0001:1 to 0.6:1, preferably in the range of 0.0002:1 to 0.3:1, and more preferably in the range of 0.0003:1 to 0.15:1.

[0107] When the second drug is entecavir, the content of the second drug in the parenteral combination administration pharmaceutical kit may be 15-35 wt% or 20-35 wt% based on 100 wt% of the entire second formulation containing the second drug and a second parenteral drug delivery vehicle. In addition, the unit dose of the second formulation containing entecavir and / or a pharma- ceutical acceptable salt thereof and a parenteral drug delivery vehicle (e.g., microspheres containing a biocompatible polymer) in the parenteral combination administration pharmaceutical kit may be 45-1,200 mg.

[0108] In one example of the present invention, when the anti-inflammatory drug of the first formulation is dexamethasone, a derivative thereof or a salt thereof, and the drug of the second formulation is entecavir or a salt thereof, the weight ratio of the first drug, dexamethasone (free base), to the second drug, entecavir (free base), in the parenteral combination administration pharmaceutical kit containing both the first formulation and the second formulation may be in the range of 0.00015:1 to 0.2:1, preferably in the range of 0.0003:1 to 0.1:1, and more preferably in the range of 0.0006:1 to 0.05:1.

[0109] In one embodiment according to the present invention, when the first drug delivery agent contained in the first anti-inflammatory preparation is microparticles, or the second drug delivery agent contained in the second preparation is microparticles, they can be prepared by a method known in the art, such as, but not limited to, solvent extraction and evaporation or spray drying. Preferably, the dexamethasone sustained-release microparticles according to the present invention can be prepared by, for example, O / W method, W / O / W method, or S / O / W method.

[0110] When the first preparation according to the present invention is microspheres containing an anti-inflammatory drug, the preparation method thereof may be carried out by an S / O / W method and specifically includes the steps of: (a1) preparing a dispersed phase by homogeneously dispersing an anti-inflammatory drug, for example, dexamethasone particles, in a solution in which a biocompatible polymer has been dissolved; (b1) preparing an emulsion by adding the dispersed phase prepared in step (a1) to an aqueous phase (continuous phase) containing a surfactant; (c1) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b1) with the continuous phase and evaporating it to form microspheres; and (d1) recovering the microspheres from the continuous phase of step (c1) to prepare sustained-release microspheres containing dexamethasone.

[0111] When the first preparation according to the present invention is microspheres containing an anti-inflammatory drug, it may be prepared by a W / O / W method, specifically comprising the steps of (a2) dissolving an anti-inflammatory drug, e.g., dexamethasone, in distilled water to prepare a W1 phase, dissolving a biocompatible polymer in a poorly water-soluble organic solvent to prepare an oil phase, and homogeneously dispersing the W1 phase in the oil phase to prepare a dispersed phase, which is a primary emulsion, (b2) adding the dispersed phase prepared in step (a2) to an aqueous solution phase (continuous phase) containing a surfactant to prepare an emulsion, (c2) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b) with the continuous phase and evaporating it to form microspheres, and (d2) recovering the microspheres from the continuous phase of step (c2) to prepare sustained-release microspheres containing dexamethasone.

[0112] The method for preparing dexamethasone sustained-release microspheres according to the present invention may be carried out by an O / W method, and specifically includes the steps of: (a3) ​​dissolving a biocompatible polymer and an anti-inflammatory drug, e.g., dexamethasone, in an organic solvent to prepare a dispersed phase; (b3) adding the dispersed phase prepared in step (a3) ​​to an aqueous solution phase (continuous phase) containing a surfactant to prepare an emulsion; (c) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b) with the continuous phase and evaporating it to form microspheres; and (d3) recovering the microspheres from the continuous phase of step (c3) to prepare sustained-release microspheres containing dexamethasone.

[0113] In the method for preparing dexamethasone microspheres according to the present invention, the biocompatible or biodegradable polymer in step (a) may be a biodegradable polymer having an intrinsic viscosity of 0.16-1.9 dL / g, or 0.10-1.3 dL / g, preferably 0.16 dL / g-0.75 dL / g, taking into consideration factors such as drug release characteristics and manufacturing process, etc. The intrinsic viscosity is measured at a concentration of 0.1% (w / v) in chloroform at 25°C using an Ubbelohde viscometer.

[0114] In one embodiment of the present invention, when the second drug delivery agent contained in the second formulation is microspheres, the microspheres may be prepared by a method known in the art, such as, but not limited to, solvent extraction and evaporation or spray drying. Preferably, the drug microspheres of the second formulation of the present invention may be prepared by, for example, O / W, W / O / W, or S / O / W.

[0115] The method for preparing drug microspheres of the second formulation according to the present invention may be carried out by an S / O / W method, and specifically includes the steps of: (a4) homogeneously dispersing drug particles in a solution in which a biocompatible polymer is dissolved to prepare a dispersed phase; (b4) adding the dispersed phase prepared in step (a4) to an aqueous phase (continuous phase) containing a surfactant to prepare an emulsion; (c4) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b) with the continuous phase and evaporating it to form microspheres; and (d4) recovering the microspheres from the continuous phase of step (c4) to prepare sustained-release microspheres containing the drug of the second formulation.

[0116] The method for preparing sustained-release drug microspheres of the second formulation according to the present invention may be carried out by a W / O / W method, and specifically includes the steps of: (a5) dissolving a drug in distilled water to prepare a W1 phase, dissolving a biocompatible polymer in a poorly water-soluble organic solvent to prepare an oil phase, and homogeneously dispersing the W1 phase in the oil phase to prepare a dispersed phase, which is a primary emulsion; (b5) adding the dispersed phase prepared in step (a5) to an aqueous solution phase (continuous phase) containing a surfactant to prepare an emulsion; (c5) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b5) with the continuous phase and evaporating it to form microspheres; and (d5) recovering the microspheres from the continuous phase of step (c5) to prepare sustained-release drug-containing microspheres of the second formulation.

[0117] The method for preparing drug microspheres of the second formulation according to the present invention may be carried out by an O / W method, and specifically includes the steps of: (a6) dissolving a biocompatible polymer and a drug in an organic solvent to prepare a dispersed phase; (b6) adding the dispersed phase prepared in step (a6) to an aqueous phase (continuous phase) containing a surfactant to prepare an emulsion; (c6) extracting the organic solvent from the dispersed phase in the emulsion state prepared in step (b6) with the continuous phase and evaporating it to form microspheres; and (d6) recovering the microspheres from the continuous phase of step (c6) to prepare sustained-release microspheres containing the drug.

[0118] In addition, in one embodiment according to the present invention, when the first drug of the first formulation and the second drug of the second formulation are both carried by one drug delivery vehicle, specifically a second drug delivery vehicle, and the second drug delivery vehicle is microspheres, the method for producing the microspheres can be the same as the method for producing the microspheres of the first formulation or the method for producing the microspheres of the second formulation.

[0119] In one embodiment of the present invention, when the mixed preparation of the second preparation containing the first anti-inflammatory drug, the second parenteral drug delivery vehicle, and the second drug is in the form of microspheres, it is prepared in a substantially similar manner to the second drug delivery vehicle, except that the first anti-inflammatory drug is included in the dispersed phase together with the second drug in the dispersed phase preparation step. In a specific embodiment, the dispersed phase is prepared by dissolving the second drug, leuprolide acetate, and the first drug, dexamethasone acetate, in dichloromethane and methyl alcohol, and adding this to a continuous phase containing a surfactant to prepare microspheres containing leuprolide and dexamethasone acetate, which are then freeze-dried.

[0120] In particular, the process for preparing microspheres according to the present invention comprises the step of adding the dispersed phase prepared in step (a) to an aqueous phase (continuous phase) containing a surfactant to prepare an emulsion.

[0121] In the method for preparing drug microspheres according to the present invention, the biocompatible or biodegradable polymer in step (a) may be a biodegradable polymer having an intrinsic viscosity of 0.16-1.9 dL / g, or 0.10-1.3 dL / g, preferably 0.16 dL / g-0.75 dL / g, taking into consideration factors such as drug release characteristics and manufacturing process, etc. The intrinsic viscosity is measured at a concentration of 0.1% (w / v) in chloroform at 25°C using an Ubbelohde viscometer.

[0122] In step (b), the content of the surfactant in the continuous phase containing the surfactant may be 0.01% by weight to 20% by weight, preferably 0.1% by weight to 5% by weight, based on the total volume of the continuous phase containing the surfactant. If the content of the surfactant is less than 0.01% by weight, a droplet-shaped dispersed phase or emulsion may not be formed in the continuous phase, and if the content of the surfactant is more than 20% by weight, it may be difficult to remove the surfactant after fine particles are formed in the continuous phase due to the excess surfactant.

[0123] The method for homogeneously mixing the biodegradable polymer solution in which the drug is dispersed and the continuous phase containing the surfactant in step (b) is not particularly limited, and can be performed using a high-speed stirrer, an in-line mixer, an ultrasonic disperser, a static mixer, a membrane emulsion method, a microfluidics emulsion method, etc. When forming an emulsion using a high-speed stirrer, an in-line mixer, an ultrasonic disperser, or a static mixer, it is difficult to obtain a uniform emulsion, so it is preferable to additionally perform a particle size selection process between steps (c) and (d) described below.

[0124] In order to prevent loss of the drug in the emulsion formed in step (b), sodium chloride may be added to the continuous phase containing the surfactant.

[0125] The method for preparing drug microspheres according to the present invention includes the steps of (c) extracting the organic solvent from the dispersed phase in an emulsion state prepared in step (b) with a continuous phase and evaporating the organic solvent to form microspheres, and (d) recovering the microspheres from the continuous phase of step (c) to prepare sustained-release microspheres containing the first drug and / or the second drug.

[0126] In step (c), when the emulsion including the droplet-form dispersed phase and the continuous phase containing a surfactant is maintained or stirred for a certain period of time, for example, 2 to 48 hours, at a temperature below the boiling point of the organic solvent, the organic solvent can be extracted into the continuous phase from the biocompatible polymer solution in which the droplet-form drug is dispersed, which is the dispersed phase. A part of the organic solvent extracted into the continuous phase can evaporate from the surface of the emulsion. As the organic solvent is extracted and evaporated from the biocompatible polymer solution in which the droplet-form drug is dispersed, the droplet-form dispersed phase can be solidified to form microspheres.

[0127] In step (c), the temperature of the continuous phase may be increased for a certain period of time in order to efficiently remove the organic solvent.

[0128] In the step (c), ethanol may be added to the continuous phase in order to efficiently remove the organic solvent.

[0129] In step (c), the temperature of the continuous phase may be additionally adjusted to modify the surface of the microspheres in order to control the initial release of the drug from the sustained-release microspheres. When adjusting the temperature by adding heat to the continuous phase for this purpose, the lower limit of the temperature range may be set to 30° C. or the glass transition temperature of the polymer, and the upper limit may be set to a temperature 30° C. higher than the glass transition temperature of the biocompatible polymer (polymer Tg+30° C.), or may be adjusted within a numerical range that is a combination of the above lower and upper limits.

[0130] In the step (d), the sustained-release microspheres can be collected using various known techniques, such as filtration or centrifugation.

[0131] Between steps (c) and (d), residual surfactant may be removed by filtration and washing, and the microspheres may be recovered by filtering again. The washing step for removing residual surfactant may be carried out using water, and may be repeated several times.

[0132] In the method for preparing drug-containing sustained-release microspheres according to the present invention, the microspheres obtained after step (d) or after the filtering and washing steps can be dried using a conventional drying method to obtain final dried microspheres.

[0133] When the first formulation and / or the second formulation are in the form of a microsphere, the same or different polymers may be used, and the weight-average molecular weight of the biodegradable polymer that can be used is not particularly limited, but the lower limit may be 5,000 or more, preferably 10,000 or more, and the upper limit may be 500,000 or less, preferably 200,000 or less.

[0134] The type of the biodegradable polymer is not particularly limited and is as described above. For example, the biodegradable polymer may be one or more selected from the group consisting of polyethylene glycol-poly(lactide-co-glycolide) block copolymer, polyethylene glycol-polylactide block copolymer, polyethylene glycol-polycaprolactone block copolymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glycose, polycaprolactone and mixtures thereof, and more specifically, polylactide, poly(lactide-co-glycolide) and polycaprolactone can be used. When poly(lactide-co-glycolide) is used as the biodegradable polymer, the molar ratio of lactic acid to glycolic acid in the copolymer may be 99:1 to 50:50, and preferably 50:50, 75:25, or 85:15.

[0135] When two or more types of biodegradable polymers are included, the above-mentioned types of polymers may be different from each other in a combination or blend, or the same type of polymer may be a combination of polymers having different intrinsic viscosities and / or monomer ratios (e.g., a combination or blend of two or more poly(lactide-co-glycolides) having different intrinsic viscosities), or the same type of polymer may have different end groups (e.g., an ester end group or an acid end group).

[0136] Examples of commercially available biodegradable polymers that can be used in the present invention include Evonik's Resomer series RG 502H, RG 503H, RG 504H, RG 502, RG 503, RG 504, RG 653H, RG 752H, RG 752S, 753H, 753S, RG 755S, RG 756S, RG858S, R202H, R203H, R205H, R202S, R203S, R205S, and Corbion's PDL 02A, PDL 02, PDL 04, PDL 05, PDLG 7502A, PDLG 7502, PDLG 7504A, PDLG 7504, PDLG 7507, PDLG 5002A, PDLG 5002, PDLG Examples of biodegradable polymers include, but are not limited to, PDLG 5004A, PDLG 5004, PDLG 5010, PL 10, PL 18, PL 24, PL 32, PL 38, PDL 20, PDL 45, PC 02, PC 04, PC 12, PC 17, PC 24, etc., either alone or in combination or in a blend. Those skilled in the art can appropriately select the appropriate molecular weight of the biodegradable polymer and the blending ratio, etc., taking into consideration the degradation rate of the biodegradable polymer and the associated drug release rate. In a specific embodiment, Resomer R755S (iv=0.50-0.70dL / g; manufacturer: Evonik, Germany) or Resomer R752H (iv=0.16-0.24dL / g; manufacturer: Evonik, Germany) can be used to prepare the microparticles according to the present invention. Alternatively, the specific polymer may be Resomer R 205S (iv=0.55-0.75 dL / g; manufacturer: Evonik, Germany) or Purasorb PDLG 7502A (iv=0.16-0.24 dL / g; manufacturer: Purac, Netherlands). Effect of the Invention

[0137] The present invention provides a parenteral anti-inflammatory formulation for preventing, reducing or treating an inflammatory response caused by a pharmaceutical product administered parenterally in a living body, or provides a parenteral formulation or kit containing a drug that can regulate the release rate of a formulation containing a parenteral second drug delivery vehicle or increase the bioavailability of a second drug. [Brief description of the drawings]

[0138] [Figure 1] 1 is a graph showing an example of Example 2 showing the improvement in bioavailability of a formulation containing leuprolide. [Diagram 2] Placebo microspheres not containing any drug were injected subcutaneously into experimental animals, and inflammation at the microsphere administration site was stained with hematoxylin and eosin (HE), after which the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation was confirmed using an optical microscope. [Figure 3a] Drug-free placebo microspheres and dexamethasone anti-inflammatory microspheres were both subcutaneously injected into experimental animals, and inflammation at the injection site was stained with hematoxylin-eosin (HE), after which the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation was observed using an optical microscope. [Figure 3b] Drug-free placebo microspheres and dexamethasone anti-inflammatory microspheres were both subcutaneously injected into experimental animals, and inflammation at the injection site was stained with hematoxylin-eosin (HE), after which the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation was observed using an optical microscope. [Figure 4a] 1 is a pharmacokinetic graph showing the time-dependent release profile of the drug in the blood when the first preparation, anti-inflammatory microspheres, was subcutaneously injected into an experimental animal. [Figure 4b] 1 is a pharmacokinetic graph showing the time-dependent release profile of the drug in the blood when the first preparation, anti-inflammatory microspheres, was subcutaneously injected into an experimental animal. [Figure 4c] 1 is a pharmacokinetic graph showing the time-dependent release profile of the drug in the blood when the first preparation, anti-inflammatory microspheres, was subcutaneously injected into an experimental animal. [Figure 5a] Drug-free placebo microspheres and anti-inflammatory microspheres were subcutaneously injected into experimental animals, and inflammation at the injection site was stained with hematoxylin-eosin (HE). The photographs show the extent of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation observed using an optical microscope. [Figure 5b] Drug-free placebo microspheres and anti-inflammatory microspheres were subcutaneously injected into experimental animals, and inflammation at the injection site was stained with hematoxylin-eosin (HE). The photographs show the extent of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation observed using an optical microscope. [Figure 6] Leuprolide microspheres and anti-inflammatory microspheres were co-injected subcutaneously into experimental animals, and inflammation at the injection site was stained with hematoxylin-eosin (HE). The photographs show the extent of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation observed using an optical microscope. [Figure 7] Histopathological slide specimens were prepared for the experimental groups G15 to G20, and the infiltration of inflammatory cells was confirmed. The results are shown below. [Figure 8] This is an indicator of systemic inflammatory response, and the concentration of TGF-β2 in the blood was confirmed using the ELISA method. [Figure 9] The photographs show residual microspheres at the administration site after placebo microspheres alone or placebo microspheres together with anti-inflammatory microspheres were administered to experimental animals. [Figure 10] Photographs showing residual microspheres at the administration site after administration of leuprolide microspheres alone or a mixture of leuprolide microspheres and dexamethasone microspheres to experimental animals. [Figure 11] 1 is a graph showing the results of blood sampling from experimental animals and measuring the donepezil concentration in the blood using LC-MS / MS. [Figure 12] 1 is a graph showing the results of blood sampling from experimental animals and measuring the blood rivastigmine concentration using LC-MS / MS. [Figure 13] This is a graph showing the results of blood sampling and measuring the concentration of finasteride microglobulins in the blood using LC-MS / MS. [Figure 14] This is a graph showing the results of blood collection from experimental animals and measuring the blood semaglutide concentration using LC-MS / MS. [Figure 15] 1 is a graph showing the results of blood sampling from experimental animals and measuring the blood octreotide concentration using LC-MS / MS. [Figure 16] 1 is a graph showing the results of blood sampling from experimental animals and measuring the blood leuprolide concentration using LC-MS / MS. [Figure 17] This is a graph showing the change in blood concentration of dexamethasone following administration of dexamethasone base, dexamethasone acetate, and A-10, which are microspheres containing encapsulated dexamethasone, which were co-administered to confirm the improvement in the bioavailability of semaglutide microspheres in Example 11. [Figure 18] These are the results of an experiment using dexamethasone microspheres and dexamethasone acetate microspheres to determine the minimum blood concentration of a drug that induces side effects. [Figure 19] These are the results of an experiment using dexamethasone microspheres and dexamethasone acetate microspheres to determine the minimum blood concentration of a drug that induces side effects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0139] Below, preferred examples are presented to aid in understanding the present invention. However, the following examples are merely illustrative of the present invention, and it will be obvious to those skilled in the art that various changes and modifications are possible within the scope of the scope and technical idea of ​​the present invention. It is natural that such changes and modifications fall within the scope of the appended claims.

[0140] Example 1: Production of anti-inflammatory microspheres

[0141] 1-1: Production of microspheres containing anti-inflammatory drugs The dispersed phase for the preparation of microspheres was prepared by mixing 1.2 g of a biocompatible polymer, Resomer RG 502H (iv=0.16-0.24 dL / g; manufacturer: Evonik, Germany), with 6.00 g of dichloromethane (manufacturer: JT Baker, USA) and dissolving until the solution became transparent, and then adding 0.8 g of dexamethasone (D50=1.8 μm; manufacturer: Farmabios, Italy) to the solution and stirring for 5 minutes or more to disperse the solution sufficiently.

[0142] The continuous phase for the production of microspheres was a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s), and 1,200 mL of the continuous phase was placed in a preparation vessel and stirred with a high-speed stirrer (L4RT, Silverson, England) at 2000 rpm while the dispersed phase was added at a flow rate of 6.0 mL per minute to form an emulsion. After the injection of the dispersed phase was completed, the emulsion was stirred at 200 rpm while maintaining the temperature at 25°C for 30 minutes, and then heated to 45°C and maintained for 3 hours to evaporate and remove the organic solvent to produce microspheres.

[0143] After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C, and the residual polyvinyl alcohol was removed by filtration and washing three times with tertiary distilled water to obtain microspheres. The microspheres obtained at this stage were freeze-dried to recover the final sustained-release microspheres containing dexamethasone. The anti-inflammatory microspheres prepared in this example were named A-1 microspheres.

[0144] Additionally, anti-inflammatory microspheres A-2, A-3 and A-4 were prepared in a manner substantially similar to that of anti-inflammatory microspheres A-1, except that the conditions shown in Table 1 below were used and the method of preparing the microspheres was carried out by membrane emulsification without using a high-speed stirrer.

[0145] Specifically, anti-inflammatory microspheres A-2 were produced using 3.5 g of Resomer R 203H (iv = 0.25-0.35 dL / g; manufacturer: Evonik, Germany), anti-inflammatory microspheres A-3 were produced using 3.5 g of Purasorb PDL 05 (iv = 0.4-0.6 dL / g; manufacturer: Purac, Netherlands), and anti-inflammatory microspheres A-4 were produced using 0.78 g of Resomer RG 752H (iv = 0.14-0.22 dL / g; manufacturer: Evonik, Germany) and 1.82 g of Resomer RG 753H (iv = 0.32-0.44 dL / g; manufacturer: Evonik, Germany).

[0146] [Table 1]

[0147] 1-2: Production of microspheres containing anti-inflammatory drugs The dispersed phase was prepared by mixing 0.39 g and 0.91 g of the biocompatible polymers RG 752H (iv 0.14-0.22 dl / g; manufacturer: Evonik, Germany) and RG 753H (iv 0.32-0.44 dl / g; manufacturer: Evonik, Germany), respectively, and 0.70 g of dexamethasone acetate (manufacturer: Pfizer, USA), with 6.50 g of dichloromethane (manufacturer: JT Baker, USA) and 4.37 g of benzyl alcohol (manufacturer: Junsei, Japan).

[0148] The dispersed phase was used after stirring for more than 30 minutes to fully dissolve it. The continuous phase was prepared by adding 2.5% (w / v) sodium chloride to a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa·s). 1,500 mL of the continuous phase was connected to an emulsifier equipped with a 40 μm diameter porous membrane, and the prepared dispersed phase was simultaneously injected to produce a microsphere suspension. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm, with the temperature of the preparation vessel maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while maintaining the temperature of the microsphere suspension at 45°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C.

[0149] The dexamethasone acetate-containing microspheres had a content of 31.76% by weight based on the total weight of the polymer and drug (100% by weight), and the microsphere size (D50) was 36.70 μm. The dexamethasone acetate-containing microspheres prepared in this example were named A-5.

[0150] Additionally, anti-inflammatory microspheres A-6, A-7, A-8, A-9 and A-10 were prepared in a manner substantially similar to that of anti-inflammatory microspheres A-5, except that the dispersed phase was prepared according to the conditions set forth in Table 2 below.

[0151] Specifically, to prepare anti-inflammatory microspheres A-6, the dispersed phase was prepared by mixing 1.60 g of the biocompatible polymer Purasorb PDLG 5002A (iv 0.16-0.24 dl / g; manufactured by Purac, Netherlands) and 0.40 g of dexamethasone acetate (manufacturer: Pfizer, USA) with 4.00 g of dichloromethane (manufacturer: JT Baker, USA) and 2.50 g of benzyl alcohol (manufacturer: Junsei, Japan). For the preparation of anti-inflammatory microspheres A-7, the dispersed phase was prepared by mixing 0.32 g and 1.28 g of the biocompatible polymers Purasorb PDLG 7502A (iv 0.16-0.24 dl / g; manufactured by Purac, The Netherlands) and Purasorb PDL 04A (iv 0.35-0.45 dl / g; manufactured by Purac, The Netherlands), respectively, and 0.40 g of dexamethasone acetate (manufacturer: Pfizer, USA) with 4.00 g of dichloromethane (manufacturer: JT Baker, USA) and 2.50 g of benzyl alcohol (manufacturer: Junsei, Japan). For the preparation of anti-inflammatory microspheres A-8, the dispersed phase was prepared by mixing 0.54 g and 1.26 g of the biocompatible polymers Purasorb PDL 02A (iv 0.16-0.24 dl / g; manufactured by Purac, The Netherlands) and RG 755S (iv 0.50-0.70 dl / g; manufactured by Evonik, Germany), respectively, and 0.20 g of dexamethasone acetate (manufacturer: Pfizer, USA) with 4.50 g of dichloromethane (manufacturer: JT Baker, USA) and 1.25 g of benzyl alcohol (manufacturer: Junsei, Japan).

[0152] For the preparation of anti-inflammatory microspheres A-9, the dispersed phase was prepared by mixing 1.40 g of the biocompatible polymer R 203H (iv 0.25-0.35 dl / g; manufacturer: Evonik, Germany), 0.60 g of dexamethasone acetate (manufacturer: Pfizer, USA) with 3.50 g of dichloromethane (manufacturer: JT Baker, USA) and 3.74 g of benzyl alcohol (manufacturer: Junsei, Japan).

[0153] For the preparation of anti-inflammatory microspheres A-10, the dispersed phase was prepared by mixing 0.88 g, 0.18 g and 0.41 g of the biocompatible polymers Purasorb PDLG 7502A (iv 0.16-0.24 dl / g; manufactured by Purac, The Netherlands), RG 752H (iv 0.14-0.22 dl / g; manufactured by Evonik, Germany) and RG 753H (iv 0.32-0.44 dl / g; manufactured by Evonik, Germany), respectively, and 0.54 g of dexamethasone acetate (manufacturer: Pfizer, USA) with 5.13 g of dichloromethane (manufacturer: JTBaker, USA), 0.73 g of dimethyl sulfoxide (manufacturer: JTBaker, USA) and 1.97 g of benzyl alcohol (manufacturer: Junsei, Japan).

[0154] [Table 2]

[0155] [Table 3]

[0156] 1-3: Preparation of microspheres containing anti-inflammatory drugs The dispersed phase was prepared by mixing 0.45 g of the biocompatible polymers RG 752H (iv 0.14-0.22 dl / g; manufacturer: Evonik, Germany) and 0.45 g of RG 753H (iv 0.32-0.44 dl / g; manufacturer: Evonik, Germany), respectively, and 0.10 g of meloxicam (manufacturer: Swati, India) with 4.50 g of dichloromethane (manufacturer: JT Baker, USA) and 1.20 g of dimethyl sulfoxide (manufacturer: JT Baker, USA).

[0157] The dispersed phase was used after stirring for more than 30 minutes to fully dissolve it. The continuous phase was prepared by adding 2.5% (w / v) sodium chloride to a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa·s). 2,000 mL of the continuous phase was connected to an emulsifier equipped with a 40 μm diameter porous membrane, and the prepared dispersed phase was simultaneously injected to produce a microsphere suspension. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm, with the temperature of the preparation vessel maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while maintaining the temperature of the microsphere suspension at 45°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C.

[0158] The meloxicam-containing microspheres had a content of 9.82% by weight based on 100% by weight of the polymer and drug combined, and the microsphere size (D50) was 60.24 μm. The meloxicam-containing microspheres prepared in this example were named A-11.

[0159] 1-4: Preparation of microspheres containing anti-inflammatory drugs The dispersed phase was prepared by mixing 0.40 g of biocompatible polymers RG 752H (iv 0.14-0.22 dl / g; manufacturer: Evonik, Germany) and 0.40 g of RG 753H (iv 0.32-0.44 dl / g; manufacturer: Evonik, Germany), respectively, and 0.10 g of ketorolac (manufacturer: Dr. Reddy's Laboratories, India) with 4.00 g of dichloromethane (manufacturer: JT Baker, USA) and 0.60 g of dimethyl sulfoxide (manufacturer: JT Baker, USA). The preparation of the continuous phase and the microspheres was carried out in a manner substantially similar to that of the meloxicam-containing microspheres in 1-3 above, to prepare the ketorolac-containing microspheres.

[0160] The ketorolac-containing microspheres had a content of 12.30% by weight based on the total weight of the polymer and drug (100% by weight), and the microsphere size (D50) was 52.28 μm. The ketorolac-containing microspheres prepared in this example were named A-12.

[0161] Example 2. Production of inflammation-inducing microspheres

[0162] 2-1: Manufacturing of Placebo microspheres The dispersed phase for the preparation of microspheres was prepared by dissolving 10 g of a biocompatible polymer, Resomer RG502H (iv=0.16-0.24 dL / g; manufacturer: Evonik, Germany), in 90 g of dichloromethane (manufacturer: JT Baker, USA) until the mixture became transparent.

[0163] A 0.1% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s) was used as the continuous phase with 2.5% (w / v) sodium chloride added. 9,000 mL of the continuous phase was connected to an emulsifier equipped with a 10 μm diameter porous membrane, and the prepared dispersed phase was injected into the continuous phase to produce microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm. The temperature of the membrane emulsifier and preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the emulsion was stirred at 200 rpm while maintaining the temperature at 25°C for 30 minutes, and then heated to 45°C and maintained for 3 hours to evaporate and remove the organic solvent.

[0164] After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25° C., and the microsphere suspension was filtered and washed three times with tertiary distilled water to remove residual polyvinyl alcohol, yielding microspheres with an average particle size of 20 μm.

[0165] The dispersed phase for the preparation of microspheres was prepared by mixing 30 g of biocompatible polymer Resomer RG502H (iv=0.16-0.24 dL / g; manufacturer: Evonik, Germany) with 120 g of dichloromethane (manufacturer: JTBaker, USA) until it became transparent. The continuous phase was a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 12,000 mL of the continuous phase was connected to an emulsifier equipped with a porous membrane with a diameter of 20 μm, and the prepared dispersed phase was simultaneously injected to prepare the microspheres. The preparation of the microsphere emulsion, evaporation and removal of the organic solvent, and washing were carried out in a manner substantially similar to that of the microspheres with an average particle size of 20 μm, and microspheres with an average particle size of 30 μm were obtained.

[0166] The dispersed phase for the preparation of microspheres was prepared by mixing 10 g of biocompatible polymer Resomer RG502H (iv=0.16-0.24 dL / g; manufacturer: Evonik, Germany) with 18.57 g of dichloromethane (manufacturer: JTBaker, USA) until it became transparent. The continuous phase was a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 2,786 mL of the continuous phase was connected to an emulsifier equipped with a porous membrane with a diameter of 40 μm, and the prepared dispersed phase was simultaneously injected to prepare the microspheres. The preparation of the microsphere emulsion, evaporation and removal of the organic solvent, and washing were carried out in a manner substantially similar to that of the microspheres with an average particle size of 20 μm, and microspheres with an average particle size of 60 μm were obtained.

[0167] Using the above method, biodegradable polymer microparticles with an average particle size of 20, 30, or 60 μm were prepared, and the inflammation-inducing Placebo microparticles prepared in this example were named B-1.

[0168] The average particle size of the microparticles was analyzed using a laser diffraction particle size analyzer. 50 mg of the composition was mixed with 1 mL of ultrapure water, mixed in a vortex mixer for 20 seconds, and then dispersed in an ultrasonic generator for 1 minute. The dispersion was placed in a particle size analyzer (Microtrac Bluewave, Japan) and measured for 20 seconds. This is the particle size that corresponds to 50% of the volume percent in the particle size distribution curve, and means the average particle size (Median Diameter), and is expressed as D50 or D(v,0.5). As a result of particle size measurement, the actual D50 values ​​of 20 μm, 30 μm, and 60 μm microspheres were 21.02 μm, 35.56 μm, and 56.49 μm, respectively.

[0169] 2-2: Preparation of donepezil microspheres The dispersed phase used in the preparation of donepezil microspheres was prepared as follows. The dispersed phase contained 580.1 g of biocompatible polymer PLA (Resomer R 203H i.v=0.25-0.35 dL / g; manufacturer: Evonik, Germany / Resomer R 205S, iv=0.55-0.75 dL / g; manufacturer: Evonik, Germany) and was prepared by mixing 396.1 g of donepezil base (manufacturer: Neuland Laboratories, India) with 3,156.2 g of dichloromethane (manufacturer: JT Baker, USA). The dispersed phase was thoroughly dissolved by stirring for more than 30 minutes before use.

[0170] The continuous phase was a 1% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s), and the continuous phase for the dispersed phase was connected to an emulsifier equipped with a 40 μm diameter porous membrane, and the prepared dispersed phase was simultaneously injected into the emulsifier to produce a microsphere suspension. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm, with the temperature of the preparation vessel maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while maintaining the temperature of the microsphere suspension at 47.5°C for 4 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 20°C.

[0171] The donepezil-containing microspheres had a drug content of 31.3% by weight based on the total weight of the polymer and drug (100% by weight), and the microsphere size (D50) was 74.47 μm. The donepezil microspheres prepared in this example were named B-2.

[0172] 2-3: Production of rivastigmine microspheres The dispersed phase was made by mixing biocompatible polymers Resomer RG 653H (IV = 0.32-0.44 dL / g; manufacturer: Evonik, Germany) 2.00 g and Resomer R 203H (IV = 0.25-0.35 dL / g; manufacturer: Evonik, Germany) 4.00 g, rivastigmine (manufacturer: Hwail Pharmaceutical, Korea) 2.70 g and pamoic acid (manufacturer: Amitychem, China) 2.09 g with dichloromethane (manufacturer: JT Baker, USA) 30.00 g until it became transparent. The biodegradable polymers were used in a ratio of 653H:203H (1:2 by weight).

[0173] The continuous phase was a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 4,500 mL of the continuous phase was connected to an emulsifier equipped with a 30 μm-diameter porous membrane, and the prepared dispersed phase was injected into the continuous phase to produce microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm. The temperature of the membrane emulsifier and preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while the temperature of the microsphere suspension was maintained at 45°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0174] The rivastigmine microspheres had a drug content of 21.24% by weight based on 100% by weight of the total of the polymer and drug, and a microsphere size (D50) of 49.02 μm. The rivastigmine microspheres prepared in this example were named B-3.

[0175] 2-4: Manufacturing of finasteride microspheres The dispersed phase was prepared by mixing 0.60 g of the biocompatible polymer Purasorb PDL 02A (IV = 0.16-0.24 dL / g; manufacturer: Purac, Netherlands) and 0.40 g of finasteride (manufacturer: Aurobindo pharma, India) in 5.40 g of dichloromethane (manufacturer: JT Baker, USA) and dissolving until the mixture became transparent.

[0176] The continuous phase was a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 1,500 mL of the continuous phase was connected to an emulsifier equipped with a 20 μm-diameter porous membrane, and the prepared dispersed phase was injected into the continuous phase to produce microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm. The temperature of the membrane emulsifier and preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while the temperature of the microsphere suspension was maintained at 40°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0177] The finasteride microspheres had a drug content of 42.6% by weight based on the total weight of the polymer and drug being 100%, a drug encapsulation rate of 106.5%, and a microsphere size (D50) of 40.43 μm. The finasteride microspheres prepared in this example were named B-4.

[0178] 2-5: Manufacturing of semaglutide microspheres The dispersed phase was prepared by dissolving 0.9 g of Purasorb PDLG 7504A (iv 0.38-0.48 dl / g, Purac, Netherlands) as a biocompatible polymer and 0.1 g of semaglutide (manufacturer: Chengdu, China) as a drug in 17.14 g of dichloromethane (manufacturer: JT Baker, USA) and 3.42 g of glacial acetic acid (manufacturer: Daejeong, Korea) until the solution became transparent.

[0179] The continuous phase was a 0.1% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 2.0 L of the continuous phase was connected to an emulsifier equipped with a porous membrane with a diameter of 40 μm, and the prepared dispersed phase was simultaneously injected to produce microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 300 rpm. The temperature of the membrane emulsifier and preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while the temperature of the microsphere suspension was maintained at 40°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0180] The semaglutide-containing microspheres had a drug content of 9.10% by weight based on 100% by weight of the polymer and drug combined, and a microsphere size (D50) of 41.77 μm. The semaglutide microspheres produced in this example were named B-5.

[0181] 2-6: Manufacturing of semaglutide microspheres (GB-7001-717 dosage form (added dosage form)) The dispersed phase was prepared by dissolving 1.85 g of Resomer RG 503H (IV = 0.32-0.44 dL / g; manufacturer: Evonik, Germany) and 3.70 g of Resomer RG 653H (IV = 0.32-0.44 dL / g; manufacturer: Evonik, Germany) as biocompatible polymers and 0.45 g of semaglutide (manufacturer: Chengdu, China) as the drug in 48.6 g of dichloromethane (manufacturer: JT Baker, USA) and 25.2 g of glacial acetic acid (manufacturer: Daejeong, Korea) until the mixture became transparent.

[0182] The continuous phase and the microspheres were produced in a manner substantially similar to the method for producing semaglutide-containing microspheres in 2-5 above, and the semaglutide-containing microspheres were produced and freeze-dried.

[0183] The semaglutide-containing microspheres had a drug content of 6.92% by weight based on 100% by weight of the polymer and drug combined, and a microsphere size (D50) of 36.20 μm. The semaglutide microspheres produced in this example were named B-6.

[0184] 2-7: Production of octreotide microspheres The dispersed phase was prepared by mixing 0.65 g of the biocompatible polymer Purasorb PDLG 7504A (iv 0.38-0.48 dl / g, Purac, The Netherlands), 0.30 g of octreotide acetate (manufacturer: Zhejiang Peptites Biotech Co., Ltd, China), and 0.05 g of pamoic acid (manufacturer: Amitychem, China or Kyeongbo Pharmaceutical, Korea) with 5.80 g of dichloromethane (manufacturer: JTBaker, USA) and 1.90 g of dimethyl sulfoxide (manufacturer: Samchun Chemical, Korea) until the mixture became transparent to the naked eye.

[0185] The continuous phase solution was prepared by adding 2.5% (w / v) sodium chloride to 0.1% (w / v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa s) aqueous solution. 2 L of the continuous phase was connected to an emulsifier equipped with a 10 μm diameter porous membrane, and the prepared dispersed phase was injected to produce microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm. The temperature of the membrane emulsifier and preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while the temperature of the microsphere suspension was maintained at 40°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0186] The octreotide-containing microspheres had a drug content of 21.75% by weight based on 100% by weight of the polymer and drug combined, and the microsphere size (D50) was 30.59 μm. The microspheres prepared in this example were named B-7.

[0187] 2-8. Manufacturing of leuprolide microspheres The dispersed phase was prepared by mixing 3.6 g of the biocompatible polymer Purasorb PDLG 7502A (iv 0.16-0.24 dl / g, Purac, Netherlands) and 0.444 g of leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India) with 6.0 g of dichloromethane (manufacturer: JT Baker, USA) and 1.722 g of methyl alcohol (manufacturer: Tedia Company, USA) until the solution became transparent to the naked eye.

[0188] A 1.0% (w / v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa s) aqueous solution was used as the continuous phase solution, and 2.5 L of the continuous phase was connected to an emulsifier equipped with a 20 μm diameter porous membrane, and the prepared dispersed phase was injected into the microspheres to produce the microspheres. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm. The temperature of the membrane emulsifier, preparation vessel, and microsphere suspension was maintained at 15°C. After the injection of the dispersed phase was completed, the mixture was stirred for 3 hours, and then the organic solvent was removed by exchanging twice with 5 L of continuous phase containing 0.5% (w / v) polyvinyl alcohol and 10% ethyl alcohol (manufacturer: Samchun Chemical, Korea). After the organic solvent was removed, the microsphere suspension was washed several times with ultrapure water to remove the residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0189] The leuprolide-containing microspheres had a drug content of 10.07% by weight based on 100% by weight of the polymer and drug combined, and the microsphere size (D50) was 32.42 μm. The microspheres prepared in this example were named B-8.

[0190] 2-9: Preparation of microspheres containing leuprolide and dexamethasone acetate The dispersed phase was prepared by mixing 3.594 g of the biocompatible polymer Purasorb PDLG 7502A (iv 0.16-0.24 dl / g, Purac, Netherlands), 0.448 g of leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India), and 0.0064 g of dexamethasone acetate with 6.0 g of dichloromethane (manufacturer: JT Baker, USA) and 1.739 g of methyl alcohol (manufacturer: Tedia Company, USA) until the solution became transparent to the naked eye.

[0191] The preparation of the continuous phase and the microspheres were carried out in a manner substantially similar to that of the preparation of leuprolide-containing microspheres in 2-8 above, and the microspheres containing leuprolide and dexamethasone acetate were produced and lyophilized. The drug microspheres produced in this example were named B-9.

[0192] 2-10: Preparation of microspheres containing leuprolide and dexamethasone base The dispersed phase was prepared by mixing 3.587 g of the biocompatible polymer Purasorb PDLG 7502A (iv 0.16-0.24 dl / g, Purac, Netherlands), 0.448 g of leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India), and 0.0128 g of dexamethasone base in 6.0 g of dichloromethane (manufacturer: JT Baker, USA) and 1.739 g of methyl alcohol (manufacturer: Tedia Company, USA) until the solution became transparent to the naked eye.

[0193] The continuous phase and the microspheres were prepared in a manner substantially similar to that of the leuprolide-containing microspheres in 2-8 above, and the microspheres containing leuprolide and dexamethasone free base were prepared and lyophilized. The drug microspheres prepared in this example were named B-10.

[0194] The properties of the microspheres prepared in Examples 2-8, 2-9, and 2-10 are shown in Table 4.

[0195] [Table 4]

[0196] The improving effects of the bioavailability of the microspheres prepared in Examples 2-8, 2-9, and 2-10 are shown in Table 5 and FIG.

[0197] [Table 5]

[0198] As shown in Table 5, the bioavailability (AUC 0-28 ) 100 as the standard, the bioavailability of leuprolide (AUC 0-28 ), with the concomitant use of dexamethasone acetate the efficacy was improved to 147%, and with the concomitant use of dexamethasone free base the efficacy was improved to 167%.

[0199] 2-11: Preparation of deslorelin microspheres The dispersed phase was prepared by mixing 8.57g and 31.43g of biocompatible polymers Purasorb PDLG 7502A (iv 0.16-0.24dl / g; manufactured by Purac, Netherlands) and Purasorb PDL 04A (iv 0.35-0.45dl / g; manufactured by Purac, Netherlands) in a weight ratio of 21:79, respectively, and 10.00g of deslorelin acetate (manufacturer: Chengdu, China) with 150.20g of dichloromethane (manufacturer: JT Baker, USA) and 93.96g of N-methyl-2-pyrrolidone (manufacturer: Ashland, India). The dispersed phase was thoroughly dissolved by stirring for at least 30 minutes before use.

[0200] The continuous phase was a 2.0% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s), and the prepared dispersed and continuous phases were injected into the emulsifier while a high-speed stirrer (Verso UHS, Silverson, England) was operated at 1,700 and 1,400 rpm in sequence to produce a microsphere suspension. The microsphere suspension was placed in a preparation vessel and stirred at 200 rpm, and the temperature of the preparation vessel was maintained at 25°C. After the injection of the dispersed phase was completed, the organic solvent was removed while the temperature of the microsphere suspension was maintained at 45°C for 3 hours. After the organic solvent was removed, the temperature of the microsphere suspension was lowered to 25°C, and the microsphere suspension was repeatedly washed with ultrapure water several times to remove the residual polyvinyl alcohol, and the microspheres were freeze-dried.

[0201] The deslorelin-containing microspheres had a content of 13.52 wt% based on the total weight of the polymer and drug (100 wt%), and the microsphere size (D50) was 50.84 μm. The deslorelin-containing microspheres prepared in this example were named B-11.

[0202] 2-12: Preparation of microspheres containing deslorelin and dexamethasone base The dispersed phase was prepared by mixing 0.93 g and 3.41 g of the biocompatible polymers Purasorb PDLG 7502A (iv 0.16-0.24 dl / g; manufactured by Purac, The Netherlands) and Purasorb PDL 04A (iv 0.35-0.45 dl / g; manufactured by Purac, The Netherlands), respectively, in a weight ratio of 21:79, with 1.04 g of deslorelin acetate (manufacturer: Chengdu, China) and 0.023 g of dexamethasone base (manufacturer: Pfizer, USA) in 16.29 g of dichloromethane (manufacturer: JT Baker, USA) and 10.19 g of N-methyl-2-pyrrolidone (manufacturer: Ashland, India).

[0203] The continuous phase and the microspheres were prepared in a manner substantially similar to that of the preparation of deslorelin-containing microspheres in 2-11 above, and microspheres containing deslorelin and dexamethasone base were prepared and lyophilized.

[0204] The deslorelin and dexamethasone base-containing microspheres had a deslorelin content of 13.25% by weight and a dexamethasone base content of 0.16% by weight based on the total weight of the polymer and drug (100%), and the microsphere size (D50) was 43.28 μm. The deslorelin and dexamethasone base-containing microspheres prepared in this example were named B-12.

[0205] 2-13: Production of Entecavir Microspheres The dispersed phase for the preparation of entecavir microspheres was prepared by dissolving 0.53g and 0.23g of biocompatible polymers Resomer RG858S (iv=1.3-1.7dL / g; manufacturer: Evonik, Germany) and 502H (iv=0.16-0.24dL / g; manufacturer: Evonik, Germany) in a weight ratio of 70:30, respectively, and 0.25g of entecavir (manufacturer: Kyeongbo Pharmaceutical, Korea) in 3.60g of dichloromethane (manufacturer: JT Baker, USA) and 5.39g of dimethyl sulfoxide, respectively, and mixing and stirring thoroughly until the mixture became transparent to the naked eye.

[0206] The continuous phase for the preparation of microspheres was prepared by adding 2.5 wt% NaCl to a 0.5% (w / v) aqueous solution of polyvinyl alcohol (viscosity: 4.8-5.8 mPa s). 800 mL of the continuous phase was placed in a preparation vessel and stirred at 3000 rpm with a high-speed stirrer (L4RT, Silverson, England) while the dispersed phase was added at a flow rate of 10.0 mL per minute to form an emulsion. After the dispersion phase was added, the emulsion was heated to 45°C while stirring at 200 rpm and maintained for 2 hours to remove the organic solvent. The microsphere suspension was then cooled to 25°C, and the residual polyvinyl alcohol was removed by filtration and repeated washing with triple distilled water to obtain microspheres. The obtained microspheres were freeze-dried to recover sustained-release microspheres containing entecavir.

[0207] The entecavir-containing microspheres had a drug content of 22.50% by weight based on the total weight of the polymer and drug being 100%, and the microsphere size (D50) was 63.63 μm. The anti-inflammatory microspheres prepared in this example were named B-13 microspheres.

[0208] Example 3: Confirmation of the pro-inflammatory properties of microcytes An experiment was conducted using rats to determine whether administration of microspheres induces inflammation in animals. Drug-free placebo microspheres with average particle sizes of 20 μm and 60 μm prepared in Example 2-1 were used as inflammation inducers.

[0209] Animal experiments were conducted in accordance with the regulations of the Animal Experiment Ethics Committee. Specifically, 5-week-old male Sprague-Dawly rats were purchased and purified for one week, then divided into two groups of four rats each. Placebo microspheres with average particle diameters of 20 μm and 60 μm prepared in Example 2-1 were subcutaneously injected into the dorsal skin of the rats at a dose of 120 mg / head. On the third and eighth days after administration, two rats from each group were sacrificed, and the injection sites were excised to confirm the difference in the degree of inflammation induction depending on the size of the microspheres administered in the acute and chronic inflammation stages.

[0210] To observe the degree of inflammation induction, the excised injection site was fixed and embedded in neutral formalin, then paraffin blocks were prepared and sliced ​​to a thickness of 4~5μm. After staining with HE (hematoxylin·eosin), the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation was observed using an optical microscope, and the results were shown in Figure 2.

[0211] In Table 6 below, the degree of inflammatory cell infiltration was determined by checking inflammatory cell infiltration in 5 randomly selected fields at 400x magnification using an optical microscope on the stained histopathological slides, and the number was ≦5 (or less) as “grade 0,” 6-20 as “grade 1,” 21-50 as “grade 2,” and over 50 as “grade 3,” and the results are shown in Table 6 as the average value for each group. In addition, the formation of fibrous connective tissue was expressed as the total number of animals in each group.

[0212] [Table 6]

[0213] As shown in the photographs in Figure 2, no angiogenesis was observed in any of the groups administered 20 μm and 60 μm-sized Placebo microspheres at the administration site on the third day after administration, which is the stage of acute inflammation induction, or at the administration site on the eighth day after administration, which is the stage of chronic inflammation.

[0214] On the third day after administration, which is the stage of acute inflammation induction, infiltration of inflammatory cells was observed in all animals in the 20μm and 60μm placebo microsphere administration groups, and weak fibrous tissue formation was observed in the 20μm placebo microsphere administration group, and on the eighth day after administration, which is the stage of chronic inflammation, similar infiltration of inflammatory cells and fibrous tissue formation were observed in all animals in the 20μm and 60μm placebo administration groups. Considering the above results, it was confirmed that inflammation was induced by the administration of microspheres when 20μm and 60μm placebo microspheres were administered subcutaneously once.

[0215] Example 4: Efficacy test of combined administration of anti-inflammatory microspheres Dexamethasone microspheres (A-1) containing 36.8% by weight of dexamethasone as a free base prepared in Example 1-1 were mixed at a dose of 0.94 mg (active ingredient content basis: 0.35 mg) or 0.23 mg (active ingredient content basis: 0.087 mg) with 120 mg of 20 μm-sized placebo microspheres and 60 μm-sized placebo microspheres prepared in Example 2-1 to prepare mixed preparations.

[0216] The mixed preparation was subcutaneously administered to the back of SD rats in a manner substantially similar to that of Example 3, and two rats per experimental group were sacrificed on days 3 and 8 after administration. The administration sites of the sacrificed rats were excised and histopathological specimen slides were prepared to test the anti-inflammatory efficacy of dexamethasone at acute and chronic inflammation stages and at different doses.

[0217] The experimental results are shown in FIG. 3a and FIG. 3b, and the degree of inflammatory cell infiltration and fibrous tissue formation at the administration site were evaluated in substantially the same manner as in Example 2, as shown in Table 7 below.

[0218] [Table 7]

[0219] As shown in the photographs of Figures 3a and 3b, no angiogenesis was observed in any of the experimental groups in which placebo microspheres with average particle sizes of 20 μm and 60 μm prepared in Example 2-1 and dexamethasone anti-inflammatory microspheres prepared in Example 1-1 were subcutaneously injected together at each injection site on the third day after administration, which is the stage of acute inflammation induction, and on the eighth day after administration, which is the stage of chronic inflammation.

[0220] As a result of the experiment, the experimental groups G4-1 to G4-4, which received a mixed preparation of placebo microspheres and dexamethasone microspheres, showed a decrease in inflammatory cell infiltration at the administration site on the third day after administration, which is the stage of acute inflammation induction, compared to G3-1 to G3-2, which received only placebo microspheres, and the effect of reducing cell infiltration was greater in G4-1 and G4-2, which received a mixed preparation containing high doses of dexamethasone microspheres (0.94 mg / head, 0.35 mg / head as dexamethasone free base), than in G4-3 and G4-4, which received a mixed preparation containing low doses of dexamethasone microspheres (0.23 mg / head, 0.087 mg / head as dexamethasone free base). No fibrous tissue formation was observed in any experimental groups on the third day after administration, which is the stage of acute inflammation induction.

[0221] The results of the experiment showed that in the experimental groups G4-1 to G4-4, which were administered a mixed preparation of placebo microspheres and dexamethasone microspheres, inflammatory cell infiltration did not occur at the administration site on the 8th day after administration, which is the stage of chronic inflammation induction, in G4-1, but did occur in G4-2 to G4-4, but was less than in G3-1 and G3-2, which were administered only placebo microspheres.On the 8th day after administration, which is the stage of chronic inflammation induction, fibrous tissue formation was observed only in the G4-4 group, with an average grade of 0.5.

[0222] From the above results, it was confirmed that the degree of inflammation was suppressed when dexamethasone microspheres were administered in combination, compared to when only placebo microspheres, which were used as inflammation-inducing microspheres, were administered.

[0223] Example 5. Characteristics of drug-releasing profanoil from anti-inflammatory microspheres Pharmacokinetic evaluation was carried out for the anti-inflammatory micronuclear cells A-2, A-3, and A-4 of Example 1 using 9-week-old SD (Sprague-Dawly) rats. The anti-inflammatory micronuclear cells A-2, A-3, and A-4 injection preparations of Example 1 were measured out to 0.06 mg / head, suspended in 0.3 mL of dispersion solvent, and then subcutaneously injected into the SD rats. 0.25 to 0.5 mL of blood was collected at predetermined time intervals, and the blood dexamethasone concentration was measured using LC-MS / MS. The measurement results are shown in Figures 4a to 4c.

[0224] As shown in Figures 4a to 4c, it was confirmed that A-2 anti-inflammatory microspheres release dexamethasone for up to 168 days, A-3 anti-inflammatory microspheres for up to 84 days, and A-4 anti-inflammatory microspheres for up to 42 days. The Cmax of A-2 anti-inflammatory microspheres was 0.5 ng / mL, A-3 anti-inflammatory microspheres for up to 0.9 ng / mL, and A-4 anti-inflammatory microspheres for up to 0.7 ng / mL, all of which were less than 1 ng / mL. In particular, A-2 anti-inflammatory microspheres and A-3 anti-inflammatory microspheres were confirmed to have a gradual release pattern. From the above results, it was confirmed that all of A-2, A-3, and A-4 microspheres are preparations that gradually release dexamethasone.

[0225] Example 6. Efficacy test of anti-inflammatory microspheres The 30 μm placebo microspheres (B-1) prepared in Example 2-1 were used as microspheres for inducing inflammation. In a manner substantially similar to that of Example 3, microspheres for inducing inflammation alone (G6-1) or in a mixed preparation with dexamethasone microspheres (G6-2 to G6-5) were prepared and administered subcutaneously to the back of SD rats at a dose of 120 mg / head or 240 mg / head.

[0226] In order to confirm whether the anti-inflammatory effect of dexamethasone was maintained until the time when the administered placebo microcytes were almost completely biodegraded, an additional test was conducted on the 33rd day after administration of placebo microcytes in addition to the 3rd and 8th days after administration, which were the time points for confirming inflammation in Example 3.

[0227] The dexamethasone microspheres administered in the mixed formulation with the inflammation-inducing microspheres were administered at a dose of 0.22 mg / head (active ingredient content basis 0.08 mg / head), 0.82 mg / head (active ingredient content basis 0.3 mg / head), or 1.63 mg / head (active ingredient content basis 0.6 mg / head). The specific experimental groups were G6-1 to G6-5, as shown in Table 8 below. Each experimental group contained a total of 13 animals, with 5 animals assigned to the 3rd day experiment, 4 animals assigned to the 8th day experiment, and 4 animals assigned to the 33rd day experiment.

[0228] In the table below, the dosage of pro-inflammatory microspheres is expressed in mg / head of microspheres, and the dosage of anti-inflammatory microspheres is expressed in mg / head of dexamethasone content, which is the active ingredient.

[0229] [Table 8]

[0230] At each time point, histopathological slide specimens were prepared using the same method as in Example 3 to confirm inflammatory cell infiltration, angiogenesis, and fibrous tissue formation. In addition, the histopathological slide specimens were stained with collagen to confirm collagen deposition at the administration site. Photographs of the stained specimens are shown in Figures 5a and 5b.

[0231] The degree of inflammatory cell infiltration and fibrous tissue formation at the administration site were evaluated in a manner substantially similar to that in Example 3, and the results are shown in Table 9 below.

[0232] [Table 9]

[0233] As shown in the analysis results in Table 9, in the case of the G6-1 group administered only 120 mg / head of 30 μm placebo, an average grade 3 infiltration of inflammatory cells was observed on the third day after administration, when acute inflammation occurs, and an average grade 3 infiltration of inflammatory cells and formation of new blood vessels and fibrous tissue were observed in all animals on the eighth day after administration, when chronic inflammation occurs.

[0234] In G6-2 to G6-5, which were administered a mixed preparation of 30 μm placebo microspheres (B-1), which are inflammation-inducing microspheres, and dexamethasone microspheres, on the third day after administration, when acute inflammation occurs, inflammatory cell infiltration was lower in all experimental groups compared to G6-1, which was administered only placebo microspheres, and the GRADE of inflammatory cell infiltration decreased as the dose of dexamethasone active ingredient increased, and no angiogenesis or formation of fibrous connective tissue was observed.

[0235] On the 8th day after administration, when chronic inflammation occurs, inflammatory cell infiltration of an average grade 3 and formation of new blood vessels and fibrous tissue were observed in all animals in G6-1, which had not received dexamethasone microspheres, whereas low-grade inflammatory cell infiltration was observed in G6-2, G6-3, and G6-5, which had received the mixed formulation, and no inflammatory cell infiltration was observed in G6-4.

[0236] In the case of the G6-5 group, which received 240mg / head of 30μm Placebo microspheres and 1.63mg / head of dexamethasone microspheres (active ingredient content basis 0.6mg / head), inflammatory cell infiltration with an average grade of 0.8 was observed on the third day after administration, when acute inflammation occurs, and inflammatory cell infiltration with an average grade of 0.5 was observed at the administration site on the eighth day after administration, which is the stage of chronic inflammation induction, and angiogenesis was observed in one animal. All inflammation-related symptoms observed in all administration groups were resolved by the 33rd day.

[0237] These results confirmed that when inflammation-inducing microspheres and dexamethasone microspheres were administered in combination, inflammatory cell infiltration and new blood vessel formation were suppressed at the acute and chronic inflammation stages compared to the group administered inflammation-inducing microspheres alone, and in particular, fibrous connective tissue formation was completely suppressed compared to the group administered dexamethasone microspheres in the chronic inflammation stage.

[0238] Example 7. Anti-inflammatory test by combined administration of drug microspheres and anti-inflammatory microspheres

[0239] 7-1: Combination use of leuprolide microspheres and anti-inflammatory microspheres After confirming that the inflammation induced by administration of drug-free placebo microspheres was alleviated when dexamethasone microspheres were administered in combination, this study was conducted to confirm whether dexamethasone microspheres also have an anti-inflammatory effect on inflammation induced by drug-containing microspheres.

[0240] Leuprolide microspheres, which are commercially available and maintain their efficacy for 3 months, were purchased and named Leuplin microspheres B-14 and used in this experiment. Male 9-week-old Sprague-Dawly SD rats were divided into 3 groups of 9 rats each, and Leuplin was injected subcutaneously once into the back of the rats at a dose of 0.5mL / head. This experiment is shown in Table 10 below as the G7-1 experimental group.

[0241] The inflammation-inducing leuprolide microspheres at 2.7 mg / head (based on the content of leuprolide free base), dexamethasone microspheres at 0.23 mg / head (based on the content of active ingredient at 0.06 mg / head), and dexamethasone microspheres at 1.04 mg / head (based on the content of active ingredient at 0.27 mg / head) were mixed to prepare a mixed formulation (G7-2 to G7-3), which was then subcutaneously injected once into the dorsal skin of SD rats at a dosage volume of 0.5 mL / head.

[0242] This experiment was performed using experimental groups G7-1 to G7-3 in Table 10 below. Each experimental group contained 9 animals, with 3 animals assigned to each group on day 1, week 4, and week 12.

[0243] Three animals per group were sacrificed 1 day, 4 weeks, and 12 weeks after administration of the test substance, and tissues from the administration site were excised to check for residual microgranulocytes, fixed in 10% neutral buffered formalin solution, embedded in paraffin, and cut into blocks of 4-5 μm thickness, stained with HE (hematoxylin·eosin) to evaluate the degree of inflammation, such as infiltration of inflammatory cells, angiogenesis, and formation of fibrous tissue. Photographs of the stained specimens are shown in Figure 6.

[0244] Figure 6 shows photographs of experimental animals in which leuprolide microspheres and anti-inflammatory microspheres were co-injected subcutaneously, and inflammation at the injection site was examined with hematoxylin-eosin (HE) staining, followed by observation under an optical microscope of the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation.

[0245] One day after administration of leuprolide microspheres and anti-inflammatory microspheres to each experimental group, the degree of infiltration of inflammatory cells and the formation of fibrous tissue at the administration site were evaluated in a manner substantially similar to that in Example 2, and the results are shown in Table 10. In the table below, the administration dose of medicinal microspheres and the administration dose of anti-inflammatory microspheres are expressed in mg / head based on the content of active ingredient.

[0246] [Table 10]

[0247] In the case of the G7-1 group that received only leuprolide microspheres at 2.7 mg / head (based on the active ingredient content), inflammatory cell infiltration with an average grade of 3.3 was observed one day after administration, when acute inflammation was induced, but no angiogenesis or formation of fibrous connective tissue was observed.

[0248] In the case of the G7-2 group, which received leuprolide microspheres at 2.7 mg / head (based on the content of active ingredient) and dexamethasone microspheres at 0.23 mg / head (based on the content of active ingredient: 0.06 mg / head), inflammatory cell infiltration of average grade 2 was observed on the first day after administration, when acute inflammation was induced, but no angiogenesis or formation of fibrous connective tissue was observed.

[0249] In the case of the G7-3 group, which received leuprolide microspheres at 2.7 mg / head (based on the content of active ingredient) and dexamethasone microspheres at 1.04 mg / head (based on the content of active ingredient: 0.27 mg / head), inflammatory cell infiltration with an average grade of 1.3 was observed one day after administration, when acute inflammation was induced, but no angiogenesis or formation of fibrous connective tissue was observed.

[0250] 7-2: Combination of placebo microspheres and dexamethasone microspheres The 30 μm placebo microspheres prepared in Example 2-1 were used as inflammation-inducing microspheres. In a manner substantially similar to that of Example 3, inflammation-inducing microspheres alone (G7-4) or a mixed preparation with dexamethasone microspheres (A-1) (G7-5, G7-6, G7-7) were prepared.

[0251] The prepared experimental preparations were subcutaneously administered to the back of SD rats at a dose of 120 mg / head of inflammation-inducing microspheres. The dexamethasone microspheres (A-1) administered in a mixed preparation with the inflammation-inducing microspheres were administered at a dose of 0.033 mg / head (0.012 mg / head based on the content of active ingredient), 0.164 mg / head (0.06 mg / head based on the content of active ingredient), or 0.82 mg / head (0.3 mg / head based on the content of active ingredient).

[0252] In order to confirm whether the administered placebo microcytes maintained the anti-inflammatory effect of dexamethasone, the inflammation confirmation time points in Example 3 were checked on days 3 and 8 after administration. At each confirmation time point, histopathological slide specimens of G7-4 to G7-7 were prepared using the same method as in Example 3, and the infiltration of inflammatory cells was confirmed. The results are shown in FIG. 7 and Table 11. Specifically, the histopathological slide specimens were stained with HE to confirm the infiltration of inflammatory cells at the administration site. The degree of infiltration of inflammatory cells at the administration site was evaluated in a manner substantially similar to that in Example 3.

[0253] 7-3: Combination of placebo microgranulocytes and dexamethasone Unlike the mixed preparation of inflammation-inducing microspheres (G7-4) or dexamethasone microspheres (A-1) used in Example 7-2, in this experiment, dexamethasone base or dexamethasone acetate not encapsulated in microspheres was mixed with the 30 μm placebo microspheres prepared in Example 2-1 as inflammation-inducing microspheres to prepare test preparations (G7-8, G7-9).

[0254] In addition, dexamethasone base and dexamethasone acetate, which were not encapsulated in microspheres, were administered as anti-inflammatory drugs at a dose of 0.06 mg / head based on the active ingredient content (G7-8, G7-9). Detailed information on the specific experimental groups (G7-8 and G7-9) is provided in Table 11 above. In the following experiment, the number of animals on the third day in each experimental group was assigned to G7-8 and G7-9, each with 4 animals.

[0255] To confirm whether the administered placebo microcytes maintained the anti-inflammatory effect of dexamethasone, the inflammation confirmation time points of Example 3 were checked on days 3 and 8 after administration. At each confirmation time point, histopathological slide specimens of G7-8 and G7-9 were prepared using the same method as in Example 3 to confirm the infiltration of inflammatory cells, and the results are shown in FIG. 7 and Table 11.

[0256] [Table 11]

[0257] As shown in the analysis results in the table above, in the case of the G7-4 group, which was administered only 120 mg / head of 30 μm placebo microspheres, an average grade 3 infiltration of inflammatory cells was observed on the third day after administration, when acute inflammation occurs, and an average grade 3 infiltration of inflammatory cells was also observed in all animals on the eighth day, when chronic inflammation occurs.

[0258] In the G7-5 to G7-7 groups, which received a mixture of 120 mg / head of 30 μm placebo microspheres and 0.03 mg / head (0.012 mg / head based on active ingredient content), 0.16 mg / head (0.06 mg / head based on active ingredient content), and 0.82 mg / head (0.3 mg / head based on active ingredient content) of dexamethasone microspheres, inflammatory cell infiltration was observed with an average grade of 0.7 to 1.7 on the third day after administration, when acute inflammation occurs, and inflammatory cell infiltration with an average grade of 0.8 to 1.3 on the eighth day, when chronic inflammation occurs. It was confirmed that the inflammatory cell infiltration decreased as the amount of dexamethasone increased.

[0259] Additionally, as an indicator of inflammatory reactions at the administration site, CD68 staining, a macrophage marker, was performed at the administration site using antibody staining. The degree of macrophage infiltration at the administration site is shown in Table 12 below. In Table 12 below, a distribution score of 1 indicates that 5-30% of the macrophages were positive in the microscopic photograph, a score of 2 indicates that 31-60%, and a score of 3 indicates that 60% or more were positive.

[0260] [Table 12]

[0261] On the third day, when acute inflammatory reactions appeared, the degree of macrophage infiltration was confirmed to be decreased in all of the dexamethasone-administered groups G7-5 to G7-9 compared to G7-4. On the eighth day, the infiltration pattern of macrophages was confirmed to be decreased in all of the dexamethasone-administered groups G7-5 to G7-9 compared to G7-4, but it was confirmed that the infiltration pattern of macrophages increased in G7-8 and G7-9, which were administered with the dexamethasone drug (without a drug carrier), compared to the third day.

[0262] As an index of systemic inflammatory response, the blood TGF-β2 concentration was confirmed by ELISA, and the blood TGF-β2 concentration is shown in FIG.

[0263] As a result of the above test, as with the histopathological data, it was confirmed that on the third day when acute inflammation occurs, blood TGF-β was reduced in all test groups G7-5 to G7-9 in which dexamethasone was administered, and on the eighth day, blood TGF-β2 was reduced more than in G7-4, which was administered 30 μm placebo microspheres alone. The manner in which dexamethasone reduced the concentration of TGF-β2 is similar to the manner in which dexamethasone reduced the degree of cell infiltration in the histopathological data. On the eighth day, it was shown that the inflammation suppression ability of dexamethasone in the microsphere formulation was better than that of dexamethasone not encapsulated in microspheres.

[0264] Example 8: Analysis of the anti-inflammatory effect of the combined preparation

[0265] 8-1: Combination formulation of drug microspheres and anti-inflammatory microspheres The degree of inflammation induction in rat animals was confirmed with or without the combined administration of drug microspheres and anti-inflammatory microspheres. The drug microspheres used were donepezil microspheres (B-2), rivastigmine microspheres (B-3), finasteride microspheres (B-4), semaglutide microspheres (B-5), leuprolide microspheres (B-8, B-9), octreotide microspheres (B-7), and deslorelin microspheres (B-11, B-12). Deslorelin microspheres and donepezil microspheres were each administered in combination with A-2 anti-inflammatory microspheres, rivastigmine microspheres and finasteride microspheres were each administered in combination with A-4 anti-inflammatory microspheres, octreotide microspheres were each administered in combination with A-3 anti-inflammatory microspheres, and semaglutide microspheres and leuprolide microspheres were each administered in combination with A-10 anti-inflammatory microspheres.

[0266] The animal experiment was conducted in accordance with the regulations of the Animal Experiment Ethics Committee. Specifically, 6-week-old male SD (Sprague-Dawly) rats were purchased and purified for one week, and then the test drugs were administered to the 7-week-old rats. Donepezil microspheres, rivastigmine microspheres, and leuprolide microspheres were administered to the thigh muscle of the right hind leg of the rats, and other drug microspheres were administered subcutaneously on the back side of the rats. The dosage, volume of administration solution, and composition of the animal groups are as follows. In Table 13, the drug dosage described in the front is the drug dosage of the second preparation, and the back is the dosage of the anti-inflammatory drug of the first preparation. In Table 13 below, the second microspheres are microspheres containing the second drug, and the first microspheres are microspheres containing the anti-inflammatory drug of the first preparation.

[0267] [Table 13]

[0268] On the third and eighth days after administration, four animals from each group were sacrificed, and the administration sites were excised to confirm the difference in the degree of inflammation induced by the administration of drug microspheres and the combined administration of anti-inflammatory microspheres at the acute and chronic inflammation stages.

[0269] To observe the degree of inflammation induction, the excised injection site was fixed and embedded in neutral formalin, then paraffin blocks were prepared and sliced ​​to a thickness of 4~5μm. After staining with HE (hematoxylin·eosin), the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation was observed using an optical microscope.

[0270] The following Table 14 shows the degree of inflammatory cell infiltration, fibrous tissue formation, and angiogenesis. Three fields were randomly selected from the stained histopathological slides at a magnification of 400 times using an optical microscope to confirm the infiltration of inflammatory cells. If the number was ≦5 (or less), it was classified as "grade 0", if it was 6-20, it was classified as "grade 1", if it was 21-50, it was classified as "grade 2", and if it was over 50, it was classified as "grade 3". Table 14 shows the average value of each group. In addition, if there was no fibrous tissue formation or angiogenesis, it was classified as "grade 0", if it was weak, it was classified as "grade 1", if it was intermediate, it was classified as "grade 2", if it was strong, it was classified as "grade 3", and if it was severe, it was classified as "grade 4".

[0271] [Table 14]

[0272] On the third day after administration of drug microspheres, the groups administered the test substances showed more pronounced subcutaneous or muscular inflammatory cell infiltration, angiogenesis, and fibrosis compared to the G8-1 control group, and the degree of inflammatory reaction varied depending on the test substance. The inflammatory reaction tended to decrease in the group administered the anti-inflammatory microspheres in combination. A similar tendency was observed in the test on the eighth day after administration. When the anti-inflammatory drug dexamethasone was encapsulated in the second drug delivery vehicle together with the drug, it also reduced inflammatory cell infiltration, angiogenesis, and fibrosis, similar to when dexamethasone was encapsulated in the first drug delivery vehicle and then administered together with the second drug delivery vehicle and the combined microspheres.

[0273] 8-2: Combination formulation of drug microspheres and anti-inflammatory drugs The degree of inflammation induction in rats was examined with or without the co-administration of semaglutide microspheres and meloxicam. Specifically, 8-week-old male Sprague-Dawly rats were purchased and purified for one week, after which the test substances were administered subcutaneously to the backs of 9-week-old rats. Semaglutide microspheres (B-6) were administered at 3.6 mg / head and meloxicam at 1.5 mg / head in a volume of 0.5 mL.

[0274] Three days after administration, each animal from each group was sacrificed and the administration site was excised to confirm the difference in the degree of inflammation induction at the acute inflammation stage. The tissues were stained by the HE method of Example 8-1, and the degree of inflammatory cell infiltration, angiogenesis, and fibrous tissue formation were confirmed by the same criteria.

[0275] The levels of inflammatory cell infiltration, fibrous tissue formation, and angiogenesis are shown in Table 15 below. It was confirmed that the meloxicam drug itself effectively reduces inflammation caused by semaglutide microspheres.

[0276] [Table 15]

[0277] Example 9. Evaluation of drug release control efficacy

[0278] 9-1: Delayed decomposition of biodegradable polymers of dexamethasone The 30 μm placebo microspheres prepared in Example 2-1 alone (G9-1 experimental group) or a mixture of placebo microspheres and dexamethasone microspheres (A-1) prepared in Example 1 (G7-5 experimental group) were administered subcutaneously to the back of SD rats, and the degree of degradation of placebo microspheres was compared. On the 16th day after administration of placebo microspheres or a mixture of placebo microspheres and dexamethasone microspheres, tissue was excised from the administration site to check the remaining microspheres. As a result, it was confirmed that the degradation of biodegradable microspheres was delayed in the group administered placebo microspheres and dexamethasone microspheres (A-1) in combination compared to the group administered placebo microspheres alone. Photographs of rats obtained from the above experimental results are shown in Figure 9.

[0279] 9-2: Delayed degradation of drug microspheres by dexamethasone In the same manner as in Example 9-1, leuprolide-containing microspheres alone or a mixture of leuprolide microspheres and dexamethasone microspheres (A-1) were subcutaneously injected once into the dorsal side of SD rats. This experiment is shown in Table 17 below as experimental groups G9-3 to G9-5, and each experimental group contained 3 animals.

[0280] In Table 17 below, the amount of residual microcytes was analyzed by calculating the area using ImageJ open source software (version 1.45s, NIH). The area in the experimental group G9-3 was set to 1 (indicated as +), and based on the residual amount in the G9-3 experimental group, an increase of 1 to 100% was indicated as ++, and an increase of 101% to 200% was indicated as +++. Photographs of rats obtained from the experimental results are shown in Figure 10. Three animals were used in each experimental group used in Table 16 below.

[0281] [Table 16]

[0282] Four weeks after administration of the test substance, the rats were sacrificed and tissues from the administration site were removed to check for residual microspheres. The results showed that the amount of residual microspheres was greater in the groups administered leuprolide microspheres mixed with dexamethasone microspheres (G9-4, G9-5) than in the group administered leuprolide microspheres alone (G9-3), indicating that the amount of residual microspheres increased as the amount of dexamethasone increased. These results confirmed that dexamethasone delays the decomposition of drug microspheres and that this property can be used to adjust the release properties of drug microspheres.

[0283] Example 10. Improved bioavailability (AUC) by combined administration of drug microspheres and anti-inflammatory microspheres For the anti-inflammatory microspheres A-2, A-3, and A-4 prepared in Example 1, 9-week-old SD (Sprague-Dawly) rats were used, and the donepezil microspheres (B-2), rivastigmine microspheres (B-3), semaglutide microspheres (B-5), and octreotide one-month sustained-release microspheres, Sandostatin Lar, which is commercially available, were purchased and named microspheres B-15 and used in this experiment. In addition, as described in Example 7, a pharmacokinetic evaluation test was performed by coadministration with the commercially available leuprolide microspheres (B-14).

[0284] In the case of donepezil microspheres, 26.04 mg / head (API basis) and anti-inflammatory microspheres A-2 at 0.3 mg / head (API basis) were mixed and administered intramuscularly.

[0285] Rivastigmine microspheres were administered intramuscularly at 8.64 mg / head (API basis) and anti-inflammatory microspheres A-4 at 0.03 mg / head (API basis) and 0.01 mg / head (API basis), respectively.

[0286] In the case of finasteride microspheres (B-4), 8.4 mg / head (API basis) and anti-inflammatory microspheres A-4 were mixed at 0.018 mg / head (API basis) and administered subcutaneously.

[0287] In the case of semaglutide microspheres (B-5), 3.6 mg / head (API basis) and anti-inflammatory microspheres A-4 at 0.054 mg / head (API basis) were mixed and administered subcutaneously.

[0288] In the case of semaglutide microspheres (B-5), 3.6 mg / head (API basis) and anti-inflammatory microspheres A-10 at 0.054 mg / head (API basis) were mixed and administered subcutaneously.

[0289] Octreotide microspheres (B-15) were mixed with anti-inflammatory microspheres A-4 at 3 mg / head (API basis) and administered intramuscularly.

[0290] In the case of leuprolide microspheres (B-14), 4.5 mg / head (API basis) and anti-inflammatory microspheres A-3 at 0.072 mg / head (API basis) were mixed and administered subcutaneously.

[0291] In the case of deslorelin microspheres (B-11), 4.7 mg / head (API basis) and anti-inflammatory microspheres A-2 at 0.06 mg / head (API basis) were mixed and administered subcutaneously.

[0292] 0.25-0.5 mL of blood was collected at predetermined time intervals, and the blood drug microsphere concentrations were measured using LC-MS / MS, and shown in the graphs shown in Figures 11-16.

[0293] In Table 17 below, the dosage of medicinal microspheres and the dosage of anti-inflammatory microspheres indicate the content (mg / head) of the active ingredient administered by administration of the microspheres.

[0294] [Table 17]

[0295] In the case of donepezil microspheres, when administered in combination with anti-inflammatory microspheres A-2 (A-2 & B-2), the AUC was improved by 277% compared to the group administered alone, and it was confirmed that the drug release mechanism was increased.In the case of rivastigmine microspheres, when administered in combination with anti-inflammatory microspheres A-4 (A-4 & B-3), the AUC was improved by 26% compared to the group administered alone.

[0296] In the case of finasteride microspheres, when administered in combination with anti-inflammatory microspheres A-4 (A-4 & B-4), the AUC was confirmed to be improved by 461% compared to the group administered alone.

[0297] In the case of semaglutide microspheres, when administered in combination with anti-inflammatory microspheres A-4 (A-4 & B-5), the AUC was confirmed to be improved by 290% compared to the group administered alone.

[0298] In the case of octreotide microspheres, when administered in combination with anti-inflammatory microspheres A-4 (A-4 & B-15), the AUC was improved by 287% compared to the group administered alone.

[0299] In the case of leuprolide microspheres, when administered in combination with anti-inflammatory microspheres A-3 (A-3 & B-14), not only was the AUC increased by 293% compared to the single administration group, but the drug release period was also increased.

[0300] In the case of deslorelin microspheres, when they were administered in combination with anti-inflammatory microspheres A-2 (A-2 & B-11), the AUC was improved by 509% compared to the group administered alone.

[0301] From the above results, it was confirmed that when anti-inflammatory microspheres A-2, A-3, and A-4 microspheres were administered in combination with drug microspheres, they improved the bioavailability (AUC) of donepezil, rivastigmine, finasteride, leuprolide, semaglutide, octreotide, and deslorelin.

[0302] Example 11. Improved bioavailability (AUC) by coadministration of semaglutide microspheres and anti-inflammatory drugs Using 9-week-old SD (Sprague-Dawly) rats, the improvement in the bioavailability of semaglutide was tested by coadministration of the semaglutide microspheres (B-6) prepared in Examples 2-6 and the anti-inflammatory microspheres prepared in Example 1 (corresponding to G3 to G6, and G9 in Table 18 below).

[0303] In addition, the above experiment was carried out by preparing a mixed formulation of the semaglutide microspheres (B-6) prepared in Example 2-6 with dexamethasone base, dexamethasone acetate or meloxicam that were not encapsulated in the microspheres, and testing the improving properties of the bioavailability of semaglutide by co-administration (corresponding to G7, G8, and G12 in the table below).

[0304] In a manner substantially similar to that of Example 9, the mixed preparation was administered to rats, and 0.25-0.5 mL of blood was collected at predetermined times for 28 days, and the concentration of semaglutide in the blood was measured using LC-MS / MS. Based on the measured drug concentration, Cmax and AUC were calculated and shown in the following table. In the following table, the semaglutide microspheres used in G11 and G12 were B-5 produced in Example 2, and the semaglutide microspheres used in G3 to G8 were B-6 produced in Example 2.

[0305] The experimental results are shown in Table 18 and FIG.

[0306] [Table 18]

[0307] As shown in the table above, when semaglutide microspheres were administered alone without combination with anti-inflammatory microspheres or anti-inflammatory drugs (G3), the AUC was 402.0 (ng*day / mL) / (mg / kg), whereas when a combination formulation of semaglutide microspheres and microspheres containing dexamethasone acetate was used (G4, G5, G6), the AUC was 1423.7, 888.2, or 1606.7 (ng*day / mL) / (mg / kg), respectively, which was significantly higher than G3 in which semaglutide microspheres were administered alone, demonstrating excellent bioavailability.

[0308] In addition, even in the case of microsphere combination preparations containing microspheres containing dexamethasone acetate, it was confirmed that G6, which contains a high content of active ingredients in the anti-inflammatory microspheres, exhibits a higher bioavailability than G4, which is administered at 0.054 mg / head as dexamethasone acetate.In addition, even in the case of combination preparations of microspheres containing semaglutide microspheres and dexamethasone acetate, when comparing the 1-month dosage form G4 with the 7-day dosage form G5, it was confirmed that the 1-month dosage form G4 exhibited a higher AUC, despite the same dosage of 0.054 mg / head as dexamethasone acetate.

[0309] In addition, combination preparations containing semaglutide microspheres (B-6) and dexamethasone base not encapsulated in microspheres or dexamethasone acetate (G7, G8) showed a significantly improved AUC, even though the dose of the anti-inflammatory drug administered was the same at 0.108 mg / head, in experimental group G6, which was a combination preparation of semaglutide microspheres (B-6) and microspheres containing dexamethasone acetate (A-10), demonstrating that the combined administration of semaglutide microspheres and anti-inflammatory microspheres is more preferable.

[0310] The graph below shows the dexamethasone release profiles of the G6, G7, and G8 groups. While the release of G7 and G8 ends in a short period of time, it can be seen that the release of A-10 in the G6 group is maintained at less than 3ng / head for more than 28 days. The semaglutide AUC of the G6 group was 1606.7ng*day / mL / mg / kg, more than twice as high as that of G7 and G8, confirming that the anti-inflammatory microspheres, which created a low and long dexamethasone release profile, have an excellent ability to improve the semaglutide AUC.

[0311] Example 12. Improvement of bioavailability (AUC) by coadministration of deslorelin microspheres and anti-inflammatory drugs Using 9-week-old SD (Sprague-Dawly) rats, the improvement characteristics of the bioavailability of deslorelin by combined administration of the deslorelin microspheres B-11 prepared in Example 2 and the anti-inflammatory microspheres prepared in Example 1 were tested.

[0312] In a manner substantially similar to that of Example 9, the mixed preparation was administered to rats, and 0.25-0.5 mL of blood was collected at predetermined times for 98 days, and the concentration of deslorelin in the blood was measured using LC-MS / MS. Based on the measured drug concentration, Cmax and AUC were calculated and shown in the table below. It was confirmed that the bioavailability of deslorelin administered in combination with anti-inflammatory microspheres was significantly improved compared to the group administered with deslorelin microspheres alone. In particular, various PK patterns were observed depending on the raw material of the anti-inflammatory preparation and the type of microspheres, and all of them showed a significantly improved AUC compared to the group administered with deslorelin microspheres alone.

[0313] [Table 19]

[0314] Example 13. Identification of toxic concentrations of dexamethasone Dexamethasone microspheres corresponding to microspheres A-13 to A-16 in Table 20 below and dexamethasone acetate microspheres corresponding to microspheres A-17 to A-22 were produced in substantially the same manner as anti-inflammatory microspheres A-2 (Example 1-1) and A-5 (Example 1-2), respectively, except that the dispersed phase production conditions and the amount of continuous phase used were different from those described in Table 20.

[0315] [Table 20]

[0316] The dexamethasone acetate microspheres or dexamethasone microspheres prepared above were administered to 9-week-old SD (Sprague-Dawly) rats to confirm the toxicity of dexamethasone. In experiment A, dexamethasone acetate microspheres were subcutaneously administered to rats at a dose of 0.3 mg / head as an active ingredient, and in experiment B, dexamethasone microspheres were administered at a dose of 1 mg / head as an active ingredient. 0.25-0.5 mL of blood was collected at predetermined time intervals, and the blood dexamethasone concentration was measured using LC-MS / MS. The rats were weighed every week for 28 days, and the rat weights and dexamethasone release profiles are shown in Figures 18, 19, Tables 21 and 22.

[0317] [Table 21]

[0318] [Table 22]

[0319] As can be seen from Figures 18 and 19 and the table, rats lost weight when the blood concentration of dexamethasone was maintained at about 4ng / mL or more for 7 days or more, as in A-17, A-18, A-19, A-20, and A-21 in Experiment A. In particular, in the high concentration test in Experiment B, rats lost weight when the blood concentration of dexamethasone was maintained at 10ng / mL or more for 7 days or more, and rats lost weight drastically or died when the blood concentration was maintained at 20ng / mL or more for 7 days or more. In addition, when examining A-16 microgranulocytes in Experiment B, it was confirmed that there was no weight loss, but normal weight gain did not occur when the dexamethasone concentration was maintained at 3ng / mL. As in the A-22 microgranulocyte test group in Experiment A, when the blood concentration of dexamethasone was maintained at less than 2ng / mL, rats did not lose weight and showed normal weight gain.

Claims

1. 1. A parenteral combination administration pharmaceutical kit comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug delivery vehicle, the first formulation comprises an anti-inflammatory first drug, or an anti-inflammatory first drug carried in a first parenteral drug vehicle; the second formulation comprises a second parenteral drug delivery vehicle and a second drug different from the drug of the first formulation; The first formulation is for preventing, reducing or treating an inflammatory response in a subject to a parenteral drug delivery system of the second formulation; A parenteral combination pharmaceutical kit.

2. 1. A parenteral combination administration pharmaceutical kit comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug delivery vehicle, the first formulation comprises an anti-inflammatory first drug, or an anti-inflammatory first drug carried in a first parenteral drug vehicle; the second formulation comprises a second parenteral drug delivery vehicle and a second drug different from the drug of the first formulation; The first formulation is for regulating the degradation of a parenteral drug delivery agent contained in the second formulation; A parenteral combination pharmaceutical kit.

3. 1. A parenteral combination administration pharmaceutical kit comprising a first formulation comprising a first drug and a second formulation comprising a second drug and a parenteral drug delivery vehicle, the first formulation comprises an anti-inflammatory first drug, or an anti-inflammatory first drug carried in a first parenteral drug vehicle; the second formulation comprises a second parenteral drug delivery vehicle and a second drug different from the drug of the first formulation; The first formulation is intended to increase the bioavailability of a second drug contained in the second formulation; A parenteral combination pharmaceutical kit.

4. The pharmaceutical kit according to any one of claims 1 to 3, wherein the second parenteral drug delivery vehicle is selected from the group consisting of a biodegradable polymer and a biodegradable lipid, and induces inflammation in a subject.

5. The pharmaceutical kit according to any one of claims 1 to 3, wherein the drug delivery vehicle is a microsphere, a liposome, a micelle, a depot, or a hydrogel.

6. The pharmaceutical kit according to any one of claims 1 to 3, wherein the first formulation and the second formulation are administered simultaneously or at different times.

7. The pharmaceutical kit according to any one of claims 1 to 3, wherein the first formulation and the second formulation are provided in a mixed formulation or separate formulations.

8. The pharmaceutical kit of any one of claims 1 to 3, wherein the first drug and the second drug are co-carried in a second parenteral drug delivery vehicle.

9. The pharmaceutical kit of any one of claims 1 to 3, comprising: the first drug; and a second formulation comprising the second parenteral drug delivery vehicle and a second drug, in a mixed formulation.

10. The pharmaceutical kit according to any one of claims 1 to 3, wherein the first drug and the second drug are individually carried on parenteral drug carriers made of the same or different materials.

11. 4. The pharmaceutical kit of claim 1, comprising a first formulation comprising a first drug carried by the first parenteral drug delivery vehicle, and a second formulation comprising a second drug carried by the second parenteral drug delivery vehicle.

12. The pharmaceutical kit according to any one of claims 1 to 3, wherein when the first formulation and the second formulation are provided as a mixed formulation, the anti-inflammatory drug is contained in an amount of 0.001 to 5.0 wt% based on 100 wt% solid content of the mixed formulation.

13. The pharmaceutical kit according to any one of claims 1 to 3, wherein the first formulation and the second formulation are provided in a mixed formulation, and when the first formulation contains a first anti-inflammatory drug carried in a first parenteral drug delivery vehicle, the first parenteral drug delivery vehicle is contained in an amount of 0.002 to 20 wt % based on 100 wt % solid content of the mixed formulation.

14. The pharmaceutical kit according to any one of claims 1 to 3, wherein the solid content of the first formulation is 0.002 to 20 parts by weight based on 100 parts by weight of the solid content of the second formulation.

15. The pharmaceutical kit of claim 1, wherein the anti-inflammatory drug has an AUC above the minimum effective concentration of the anti-inflammatory drug that is 10% or less of the AUC of a daily dosage formulation.

16. 2. The pharmaceutical kit of claim 1, wherein the parenteral drug delivery vehicle is provided for intra-articular, subcutaneous, intradermal, intramuscular, intratumoral, intraocular, intravitreal or intratympanic administration.

17. The pharmaceutical kit according to any one of claims 1 to 3, wherein the drug delivery vehicle is a microsphere having an average particle size of 10 to 100 micrometers.

18. The pharmaceutical kit according to any one of claims 1 to 3, further comprising a local anesthetic component.

Citation Information

Patent Citations

  • Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere

    CN104548210A

  • A biodegradable polymer matrix for sustained delivery of local anesthetics

    JP1996503695A

  • Amorphous poly(d,l-lactide) coating

    JP2008539002A

  • Compositions and methods for delivery of therapeutic agents

    JP2019504002A

  • Lipid nanoparticles containing lipophilic anti-inflammatory agents and methods of use thereof

    JP2019514979A